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Abstract 
 
The increasing number of lipophilic drug candidates in development in the 
pharmaceutical industry calls for advanced drug delivery systems with increased 
bioavailability less day-to-day and food-intake-dependent. Many of these drug 
candidates possess poor water solubility, so that their dissolution rate in the 
gastrointestinal tract (GIT) limits their absorption following oral administration. 
In the past few decades, various lipid-based formulations have been investigated 
to enhance the bioavailability of such challenging drug candidates and to increase 
their clinical efficacy when administered orally.  
Recently, self-emulsifying drug delivery systems (SEDDS) have attracted 
increasing interests and, in particular, self-nanoemulsifying drug delivery systems 
(SNEDDS). SEDDS and SNEDDS consist in micro- or nano-emulsions of oil 
containing the drug that spontaneously form in aqueous media on mild agitation. 
Usually, they use high amounts of surfactant that may cause degradation and 
instability of the drugs, being moreover toxic for the gastrointestinal tract.  
The aim of the present thesis was the preparation of novel self-nanoemulsifying 
drug delivery systems to overcome the shortages of conventional SEDDS or 
SNEDDS. 
To reduce the amount of surfactant, we formulated first a self-nanoemulsifying 
drug delivery system containing high proportion of essential lemon oil, that was 
characterized in terms of drug solubility, formulation stability, viscosity, emulsion 
droplet size, ζ-potential and in vitro drug release.  
Then, a pH-sensitive SNEDDS was developed that emulsify only at basic pHs.  
The goal was to protect the lipophilic drugs from the harsh acidic environment in 
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stomach and render it available in the enteric tract where the bioactive compound 
should be absorbed. 
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Chapter I    General Introduction 
1. Oral delivery systems for lipophilic drugs 
Oral delivery route is the most convenient route for drug administration to achieve 
desired therapeutic effects and the greatest degree of patient compliance, especially 
for chronic condition diseases [1]. Despite some clinical oral formulations have been 
developed, their low oral bioavailability is still a major hurdle, leading to challenges 
for pharmaceutical manufacturers to design delivery systems that can provide 
improved pharmacokinetic profiles and therapeutic responses [2-4]. Currently, many 
efforts such as efflux pump inhibitors, permeation enhancers and drug nanonization, 
have been made to overcome the challenges of low oral bioavailability resulting from 
low drug solubility, poor permeation and enzymatic degradation, which limiting drug 
effective delivery[5]. 
1.1. Physicochemical properties of the drugs 
1.1.1. Biopharmaceutics classification system (BCS) 
The Biopharmaceutics classification system (BCS) is a guide for predicting the 
intestinal drug absorption provided by the U.S. Food and Drug Administration (FDA). 
BCS is a useful tool for decision-making in formulation development from a 
biopharmaceutical point of view [6].  
On the basis of drug solubility and intestinal permeability, BCS categorize the 
drugs into four categories, as follows [7-9]: 
 Class I - high permeability, high solubility (Example: metoprolol),  
 Class II - high permeability, low solubility (Example: silibinin, 
ibuprofen),  
 Class III - low permeability, high solubility (Example: cimetidine), 
8 
 
 Class IV - low permeability, low solubility (Example: hydrochlorothiazide, 
Bifonazole)  
As recommended by FDA, the solubility class boundary is based on the highest 
dose strength of an immediately release product. A drug substance is considered 
highly soluble when the highest dose strength is soluble in 250 ml or less of 
aqueous media over the pH range of 1-6.8, while a drug substance is considered to 
be highly permeable when the extent of absorption in humans is determined to be 
85% or more of an administered dose based on a mass balance determination or in 
comparison to an intravenous reference dose [9]. The low permeability of Class II 
and Class IV drugs renders them poorly bioavailable, so reducing their potential 
pharmaceutical effect or requiring high dosage to achieve it [10, 11].  
Biopharmaceutics classification system (BCS) and viable formulation options based 
on the BCS are summarized in Figure 1.1. 
 
Figure 1.1 Biopharmaceutics classification system (BCS) and viable formulation 
options based on the BCS [12]. 
1.1.2. Physicochemical properties of lipophilic drugs 
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More than 40% of new drug candidates of recent years possess poor aqueous 
solubility, and approximately 40% of the marketed immediate-release (IR) oral drugs 
are categorized as practically insoluble [12]. The term “lipophilic drugs” roughly 
describes a heterogeneous group of molecules that exhibit poor solubility in water, 
but certainly not always, are soluble in various organic solvents [13]. Usually, the 
terms practically insoluble (< 0.1 mg/ml), very slightly soluble (0.1–1 mg/ml), and 
slightly soluble (1–10 mg/ml) are used to categorize lipophilic drug substances [14]. 
 Partition coefficient, P, is the ratio of the concentrations of a compound in a 
mixture of two immiscible phases at equilibrium, which particularly are water and 1-
octanol in chemical and pharmaceutical sciences [15]. P is a measure of how 
hydrophilic ("water-loving") or lipophilic ("water-fearing") a chemical substance is 
[16]. The poorly soluble drug candidates exist in two types of molecule structure, 
“grease ball” and “brick dust” [17]. Grease ball molecules are highly lipophilic with 
high log P due to no interactions with water. Brick dust molecules have melting point 
above 200 ℃ and low log P. Their poor solubility in water is caused by the strong 
intermolecular bonding and high lattice energy in solid state [18].  
1.1.3. Drug stability 
Drugs that are instable in the gastrointestinal tract (GIT) may undergo degradation. 
For instance, acid-labile drugs to be released in the small intestine must be 
protected with enteric coating.  
Drug stability studies should address the sensitivity of dissolved drug to acids, 
alkalis, and oxidation as well as solid-state humidity-related, thermal, and photo-
degradation which are very useful in drug delivery system design [13, 19]. 
 As mentioned above, many drugs are unstable under certain chemical conditions, 
such as pH, ionic strength, or ingredient interactions. In this case, it is necessary to 
protect the active component from any constituents or environmental conditions that 
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promote chemical degradation. On the other hand, a food or drink product may also 
contain a number of functional ingredients that adversely interact with each other 
and cause physical instability [20]. In this case, it may be necessary to isolate the 
different active ingredients from each other to avoid undesirable physical changes in 
the systems [21]. 
An ideal oral drug delivery system must protect the drug from the degradation in 
the gastrointestinal tract, and deliver the bioactive compounds to the specific area 
where it is better absorbed. According to these reasons, plenty of efforts in oral drug 
delivery have been made on improving drug stability in the GIT, increasing drug 
solubility and further the bioavailability [22]. 
1.2. Advantages of oral delivery systems 
Oral administration is the most widely accepted and preferred route for 
pharmaceuticals, due to its high convenience and better patient compliance [23]. 
Oral administration of drugs can avoid hospitalization, sterile manufacturing and 
trained personnel assistance, so reducing the cost of the health treatment [24]. 
Pharmaco-economic analyses were performed in clinical trials to evaluate the 
economic effectiveness of various oral drugs and to make a contrast with the cost of 
infusion administration [25].   
In 2006, Cassidy, J. et al. [26] compared the costs for oral administration of 
capecitabine and intravenous administration of 5-fluorouracil/leucovorin (5-FU/LV), 
that are two chemotherapeutic drugs. The total costs of the two therapies were 
calculated by evaluating the following direct medical cost: 
Cost of chemotherapy drugs; 
 Cost of visits for drug administration; 
 Cost of hospital use; 
 Cost of physician consultations for adverse events and for treating them;  
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Cost of ambulance trips. 
Data analysis showed that when the ‘societal costs’ were added, the total costs 
were approximately £3500 for the oral capecitabine versus £8500 of 5-FU/LV. For 
this reason, based on the economic effectiveness, they termed capecitabine as a 
‘dominant’ treatment strategy. 
Besides, higher drug dosage may lead to side effects and wastage of the drugs, 
which is not economically tolerable, especially for some kinds of expensive drugs 
[27].  
1.3. Challenges in the oral drug delivery 
Regardless of many advantages, the development of oral delivery route still 
represents a great challenge owing to peculiar physicochemical properties of 
lipophilic drug candidates, and physiological barriers such as gastrointestinal 
instability, pre-systemic metabolism and efflux pump [28]. Upon oral administration, 
lipophilic drug in a dosage form is easily ingested by patients, travels in the GIT 
passing through an extremely various environment. When drug transits from a 
strong acidic pH in stomach to basic environment of the intestine, it encounters 
harsh pH changes, but also different digestive enzymes and the resident microflora 
[6, 29]. After the digestive journey, only a fraction of dose is available to systemic 
circulation for execution of therapeutic response [30]. In view of this, the principal 
challenges to the oral delivery are classified into physicochemical properties of 
drugs and physiological barriers posed by human body (Figure 1.2). 
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Figure 1.2 Schematic representation of the various challenges to the oral delivery of 
drugs.[24] 
1.3.1. Solubility of drug substances 
A plenty of organic materials are poorly soluble in water. The poorly water-soluble 
drugs are typical examples. Poor solubility of a drug is in most cases associated with 
poor bioavailability. As reported by CA Lipinski [31], 31.2% of 2246 compounds 
synthesized in academic laboratories between 1987 and 1994 had solubility equal to 
or less than 20 μg/ml. Furthermore, in drug discovery, about 40% of new drug 
candidates display poor solubility in water, which leads to low bioavailability, erratic 
absorption, high intra-subject and inter-subject variability and lack of dose 
proportionality [32].  From a physicochemical point of view, poor aqueous solubility 
and low dissolution rate are the major factors that affect oral delivery of many 
existing lipophilic drugs [33]. Improving the drug solubility might only solve one 
aspect of the problem but it is a starting point to design efficient pharmaceutical 
formulations [25]. 
1.3.2. Gastrointestinal transit 
Human digestive system is complicatedly designed to safely, selectively, and 
effectively absorb as many nutrients as possible from our diet. In the case of drug 
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delivery, after the oral administration, drug candidates have to reach final absorption 
site – intestine. However, the gastrointestinal tract (GIT) presents various chemical 
and enzymatic barriers that affect delivery of drugs [34]. During the drug transit, the 
pH of the GI tract lumen rises from the strongly acidic (pH 1.0–2.0) in the stomach, 
to 5.0–6.0 in the duodenum, to basic (pH 7.0-9.0) in the jejunum [35]. On the other 
hand, variety of enzymes that include lipases and proteases also function to initiate 
foodstuff digestion and destroy unwanted pathogens and toxins [36]. Furthermore, 
the gastrointestinal transit time is another factor that significantly affects oral 
bioavailability and efficacy of many drugs. Many efforts have been done to enhance 
the duration for absorption, like the dosage form mucoadhesive. The use of 
mucoadhesives can increase local drug concentrations for absorption enhancement, 
improve the efficiency for prolonging drug resistance time, and in some cases 
restrict absorption to a specific site in the intestine [37, 38]. So far, various types of 
approaches have been successfully developed to extend the gastrointestinal transit 
time, further to improve the intestinal permeability and to enhance the oral 
bioavailability [39]. 
1.3.3. Drug metabolism and efflux pump 
The metabolism of drug candidates and their efflux in the intestine during the 
absorption process represent another problem arising when the drugs are orally 
administered [40]. Drug metabolism is the biochemical modification of 
pharmaceutical substances or xenobiotics respectively by living organisms, usually 
through specialized enzymatic systems before reaching the systemic circulation. 
The rate of metabolism determines the duration and intensity of a drug's 
pharmacological action [41]. After oral administration, the drug is absorbed by the 
digestive system and enters into the liver via the portal vein, where a fraction of 
absorbed dose is metabolized [42]. In the issue, the systemic availability of the drug 
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is greatly reduced, in turn, affecting the amount of the drug reaching the final 
absorption sites. Transmembrane efflux of drugs is a mechanism responsible for 
moving foreign compounds, like drug substance, toxic substances, and antibiotics, 
out of the cell via a clinically significant systematic transportation system such as P-
glycoprotein (P-gp), flurochrome efflux, methotrexate efflux (folates), etc. [24, 43, 44]. 
P-glycoprotein (P-gp) is extensively distributed and expressed in the intestinal 
epithelium where it pumps drugs back into the intestinal lumen. P-gp inhibitors are 
explored for overcoming multidrug resistance and poor bioavailability problems of 
various drug substrates [45]. Therefore, the drug metabolism is considered as major 
contributor for low oral bioavailability of many drugs. 
1.4. Approaches for enhancement of oral bioavailability  
 The common approaches to improve the systemic bioavailability of drugs are to 
deliver them by alternative administration routes such as oral, transdermal, nasal, 
vaginal or rectal. Among these routes, oral administration is the most convenient 
way to achieve the desired therapeutic effects.  
Numerous pharmaceutical scientists have logically focused on oral administration 
route to effectively enhance the bioavailability of the drug substances.  The key 
approaches to maximize oral drug absorption are described as follows:  
(1) By using efflux pump inhibitors to improve the efficiency of drug transport;  
(2) By using permeation enhancers to inhibit drug degradation and improve 
permeability;  
(3) Modifying the physicochemical properties of drugs for improving drug solubility, 
stability and dissolution rate;  
(4) Designing the specialized formulation such as nanoparticles, micro-particles 
and liposomes that improve the drug solubility and protect drugs from harsh 
environment of the gastrointestinal tract;  
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 (5) Developing stimuli-responsive systems for controlled drug delivery [46, 47]. 
Figure 1.3 summarizes the various strategies that have been investigated and 
proposed to  improve the oral bioavailability of drug substances. 
 
Figure 1.3 Strategies to improve the oral bioavailability of drug substances [24]. 
1.4.1. The use of efflux pump inhibitors 
In recent years, the impact of efflux pumps on the therapeutic activity of drugs has 
been well established. The efflux transporters such as P-gp, the breast cancer 
resistance protein (BCRP) and the multidrug resistance related protein (MRP), which 
have been identified to be over-expressed in tumor cells, are also widely distributed 
throughout normal tissues in humans [48]. In the view of this, approaches to identify 
efflux pump substrates and inhibitors as well as strategies to overcome the barrier 
caused by efflux pumps have been investigated (Figure 1.4). Several studies have 
demonstrated the possibility of using P-glycoprotein inhibitors as an attempt to 
improve the efficiency of drug transport across the epithelia, thus resulting in 
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enhanced oral bioavailability. As reported by Kwak et al [49], HM30181, a newly 
developed P-gp inhibitor, showed promising results for increasing oral absorption of 
some drugs. Nevertheless, the efflux pump inhibitor approach is scarcely used 
clinically owing to associated clinical complications such as suppression of immune 
system thus causing long term medical complications[24]. Therefore, safer 
alternatives with similar properties can be sought to enable the safe use for chronic 
therapy. 
 
Figure 1.4 Various P-gp based approaches for improving the oral bioavailability of 
drugs.[24] 
1.4.2. The use of permeation enhancers 
The membrane permeation, which is governed by the drug lipophilicity limits the 
therapeutic efficacy of many drugs. Permeation enhancers can improve the 
permeation of drug substances through intestinal barriers. In general, permeation 
enhancers improve drug absorption by the following mechanisms:  
(1) Disruption and opening of tight junctions to increase paracellular permeability;  
(2) Decrease of in the mucus viscosity; 
(3) Increase of membrane fluidity specific to their category [2, 50].  
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A large variety of permeation enhancers have been studied to improve the 
intestinal permeability of drugs. These include lipids, surfactants, fatty acids, 
medium chain glycerides, chitosan and other derivatives. Mechanistically, they are 
found to modulate the activity of the P-gp efflux pump, increase drug solubility, 
facilitate wetting, and then increase permeability across the gastrointestinal tract. 
Some of these enhancers have been developed to the stage of initial clinical trials. 
Several enhancers seem to have potential to improve oral bioavailability without 
causing significant gastrointestinal tract damages [51]. 
1.4.3. Modification of the physicochemical properties of drugs  
The physicochemical properties of drug substances dramatically influence their 
performance. Modification of the physicochemical properties of the drug molecules 
has already been confirmed to be an important approach for the development of 
effective oral delivery systems. In order to exert maximum therapeutic action, the 
drugs must be absorbed into the systemic circulation via passive diffusion to achieve 
high plasma concentrations. For the poor water soluble drugs, dissolution rate of the 
drugs is regarded as the limiting step for the absorption process, so their solubility 
should corresponds to the dissolution rate in gastrointestinal tract to achieve 
effective absorption. The drug molecular modification for solubility increase can be 
achieved by various approaches, including salt and prodrug formation, complexation, 
polymorphism or preparation of analogues. The molecular size of drugs is another 
factor that affects their bioavailability and absorption. Recently, various nanonization 
approaches have been sought to increase the dissolution rates of numerous drugs. 
Nanonization can lead the improvement on drug solubility and pharmacokinetics, 
further it may also decrease systemic side-effects [52]. 
1.4.4. The use of specialized formulation vehicles 
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Numerous specialized strategies have been attempted to enhance the 
bioavailability of drugs by using of lipid based formulation (liposomes, lipid–drug 
conjugates, layersomes, nano/micro-emulsion, self-emulsifying drug delivery 
systems), polymer based formulation (polymeric micelles, polymeric nanoparticles), 
nanocarrier based approaches (nanosuspension, carbon nanotubes, nanocrystals) 
to successfully deliver lipophilic drugs via the oral route. These approaches improve 
the oral bioavailability of lipophilic drugs by different mechanisms including improved 
drug solubilisation, absorption and protection against enzymatic and 
physicochemical degradation. Furthermore, smaller droplet/particle size of these 
systems increases the interface between the lipophilic droplet and the aqueous gut 
medium to facilitating a homogeneous and wide distribution of the drug along the 
GIT.  
1.4.5. Stimuli-responsive drug delivery systems 
The therapeutic efficacy of the drug delivery systems depends on the capacity to 
release the drug to the specific region at the right time with a desired dosage to 
achieve the therapeutic response. Various stimuli-responsive materials which are 
sensitive to physical stimuli (temperature, electric charge, electrochemical, light, 
magnetic, and ultrasonic), chemical stimuli (pH, ionic, and redox), or biological 
stimuli have been sought for controlled drug delivery systems. For instance, pH-
sensitive systems have been widely used for drug delivery in colon targeted release 
and cancer therapy according to the pH change in different tissues such as tumour 
and normal tissues, extracellular and cellular, gastric fluids and intestinal tract. 
2. Nanotechnology in oral drug delivery 
Nanotechnology has been defined as “ the understanding and control of matter at 
dimensions of roughly 1 to 100 nanometers, where unique phenomena enable novel 
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applications” [53]. Recently, nanotechnologies have gained attention to enhance the 
oral bioavailability of drugs in their dosage forms, especially lipophilic drugs. The 
most acclaimed and prospective nanotechnology strategies used in oral drug 
delivery include lipid based nanoparticles (nanoemulsions, self-nanoemulsifying 
drug delivery system (SNEDDS), solid lipid nanoparticles, lipid nanocapsules 
nanosuspension, liposomes, layersomes, liquid crystalline nanoparticles, lipid-drug 
conjugates); Polymer based nanocarriers (polymeric nanoparticles, polymeric 
micelles, polymer-drug conjugates); Drug nanocrystals; Dendrimers; Carbon 
nanotubes; Silica and silicon nanoparticles; Nanogels and so on. Moreover, 
nanotechnology-based therapeutic products had been validated through the 
improvement not only for the previously approved drug substances, but also for 
many new drug candidates [54]. The use of nanotechnology in oral drug delivery 
may radically change the way we exploit drugs and the way we take drugs, thus 
providing an ideal approach for chemotherapy [55]. Numerous types of nanocarriers 
and formulations available for oral delivery have been used as delivery vehicles to 
develop effective therapeutic modalities, as shown in Figure 1.5. The variety and 
advantages associated with them have been discussed in the subsequent sections. 
The potential mechanisms responsible for enhanced oral delivery observed with 
nanocarriers are shown in Figure 1.6. 
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Figure 1.5  Examples of various nano-architectures available for oral drug delivery.[1] 
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Figure 1.6 Overview of nanocarriers-mediated mechanisms leading to enhanced 
oral drug delivery.[1] 
2.1. Lipid based nanoparticles 
2.1.1. Nanoemulsions 
Nanoemulsions are non-equilibrium, heterogeneous systems composed of oil 
droplets dispersed in an aqueous medium and stabilized by surfactant molecules. In 
a nanoemulsion, the oil droplets serve as the reservoir for hydrophobic drugs [52]. 
Moreover, nanoemulsions are regarded as kinetically stable, isotropic and 
transparent without any apparent coalescence during the long time storage. The 
nanoemulsions are usually stabilized by large amount of surfactants, which can 
improve drug solubilisation, protect active compound against physicochemical and 
enzymatic degradation and modify the permeability of the GIT membrane. Non-ionic 
surfactants are commonly preferred due to their less toxicity, less affected by pH 
and ions than ionic and amphiphilic surfactants, and better compatibility with 
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biological systems [56]. Combinations of different surfactants have also been 
employed to decrease the droplet size and improve the stability of nanoemulsions. 
Methods used for the production of nanoemulsions include high-pressure 
homogenization, microfluidization, ultrasonication, spontaneous emulsification and 
so on [57]. The advantages of nanoemulsions are increased drug loading, tissue 
targeting and enhanced permeability. 
2.1.2. Lipid-drug conjugates 
To overcome the limitation of limited loading capacity for highly potent hydrophilic 
drugs and drug expulsion during storage, lipid-drug conjugates have been made. 
Lipid-drug conjugates nanoparticle are prepared either by formation of a salt with a 
fatty acid or alternatively by covalent linkage (e.g. to ester or ethers) [58]. Further 
process is perform an aqueous surfactant solution to a nanoparticle formulation 
using high pressure homogenisation [59]. The lipids that can be used for formulation 
of lipid–drug conjugates include phospholipids, fatty acids such as stearic acid, oleic 
acid, docosahexaenoic acid, etc. and lipoamino acids [24]. 
 
2.1.3. Solid lipid nanoparticles (SLNs)  
Solid lipid nanoparticles (SLNs) are composed of melt-emulsified solid lipids like 
highly purified triglycerides, monoglycerides, hard fats, complex glyceride mixtures 
as matrix materials. As they are derived from biodegradable and compatible lipids, 
SLN represents a comparatively stable system with protective effects against 
serious drug toxicity and harsh external environment in comparison to the 
conventional nanoparticles. In addition, they also offer the advantages of avoidance 
of organic solvents in their preparation, controlled release of drugs and excellent 
tolerability [60]. Of the available methods for preparation, cold high-pressure 
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homogenisation process, hot homogenization of melted lipids at elevated 
temperatures and microemulsion technology are considered as the most feasible 
methods for large scale production of SLNs [61]. Although solid lipid nanoparticles 
(SLNs) have attracted increasing attention due to its advantages, SLNs have several 
limitations, for example, low loading efficiency for some drugs which owing to the 
densely packed lipid crystal network. Furthermore, SLNs also show considerable 
expulsion of the drug during storage [3]. The schematic structure of SLNs is shown 
in Figure 1.7. 
 
 
Figure 1.7 Schematic differences between nanocapsule, polymeric nanoparticle 
(PNP), and solid lipid nanoparticle (SLN) drug delivery systems.[62] 
2.1.4. Lipid nanocapsules (LNCs)  
Lipid nanocapsules (LNCs) provide a new nanotechnology which contributes to 
oral drug delivery development. LNCs are another kind of lipid nanoparticles, 
composed of an internal liquid or semi-liquid oil core and an external lipid layer solid 
as a core-shell structure [63]. LNCs with the unique properties such as controlled 
release profiles and high bioavailability, represent a promising biocompatible drug 
delivery platform in nanometer range with narrow size distribution [64]. The phase 
inversion temperature (PIT) method proposed by Shinoda and Saito [65] led to lipid 
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nanocapsules preparation with good mono-dispersion. LNCs prepared by PIT 
method is based on three main components: an oil phase, an aqueous phase and a 
non-ionic surfactant. Furthermore, the temperature cycling process crossing the 
phase-inversion zone (PIZ) plays another role on LNCs formulation. Increasing the 
number of cycles promotes LNC formation and improves the quality of LNC 
dispersion [66]. Recently, many lipophilic drugs have been developed in LNCs form 
for instance, ibuprofen loaded LNCs for pain treatment; indinavir, an inhibitor of HIV1 
protease; various hydrophobic anticancer agents. Consequently, LNCs provide an 
attractive drug delivery approach for highly lipophilicity drug substances that are 
usually unsuitable for oral use. 
2.1.5. Nanosuspensions 
Nanosuspensions are nanoscale colloidal dispersion of solid drug particles which 
are stabilized by surfactants, polymers or a combination of both. The key difference 
from conventional suspensions is that the particle size distribution of the solid 
particles in nanosuspensions is usually < 1 µm [67]. Nanosuspensions engineering 
processes presently used are media milling, high pressure homogenization, 
microprecipitation-high pressure homogenization, emulsion diffusion method and 
melt emulsification method. Owing to the enhanced drug solubility, increased 
surface-volume ratio of the nanocrystals, and improved dissolution rate, oral 
nanosuspensions have been specifically used. Furthermore, nanosuspensions are 
available in various dosage formats such as tablets, pellets, and capsules following 
different manufacturing techniques [18]. Nevertheless, the major challenges in 
nanosuspensions preparation are maintaining colloidal stability and particle size of 
the nanosuspensions during storage. The appropriate selection of the surfactants 
and/or steric stabilizers and the method of fabrication have been sought to prevent 
25 
 
the nanocrystal aggregation to achieve the nanosuspensions with long-term storage 
and physiological stability. 
2.1.6. Liposomes  
Liposomes are a form of self-assembled lipid bilayer vesicles which composed of 
one or more aqueous compartments are completely enclosed by hydrophilic and/or 
hydrophobic molecules. Due to the core (aqueous)-shell (lipidic) structure, 
liposomes are available for encapsulating hydrophilic drugs in the aqueous core, 
hydrophobic agents in the lipidic shell, meanwhile, amphiphilic molecules distributed 
through the hydrophobic-hydrophilic layers. In addition, using biologically and natural 
lipids makes liposomes highly biocompatible and suitable for in vivo use [68]. 
Recently, research on liposomes technology has been extensively investigated for 
the delivery of various therapeutic and bioactive agents, decreasing toxicity and 
increasing their accumulation at target sites.  Nitesh Kumar et al [69] developed 
lecithin-based silymarin liposomes. The results showed that incorporating 
phytosomal form of silymarin in liposomes had better in vitro and in vivo 
hepatoprotection and better anti-inflammatory effects in histopathological changes. 
Therefore, liposomes can be used in the oral delivery of lipophilic drugs to increase 
its oral bioavailability. 
2.1.7. Liquid crystalline nanoparticles (LCNPs)  
Liquid crystalline nanoparticles (LCNPs), which combine the properties of both 
liquid and solid states, are self-assembled from polar amphiphilic lipids in the 
presence of excess water. LCNPs are generally prepared by dispersing the liquid 
crystalline matrix formed into water phase using high-energy fragmentation, such as 
ultrasonication, microfluidization, or homogenization [70]. Normally, LCNPs enhance 
the oral bioavailability of lipophilic drug by improvement of bioadhesiveness, 
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membrane fusing properties, superior encapsulation, solubilization, etc. [24] . Ni 
Zeng et al [70] developed self-assembled LCNPs consisting of soy 
phosphatidylcholine and glycerol dioleate for oral delivery of paclitaxel. The results 
of this study suggest that LCNPs could be a promising approach for enhancing the 
oral bioavailability of lipophilic drugs and agents. 
2.1.8. Self-nanoemulsifying drug delivery system (SNEDDS)  
Self-nanoemulsifying drug delivery systems (SNEDDS) are isotropic mixtures of 
oil, surfactant, co-surfactant and drug that rapidly form fine oil-in-water (o/w) 
nanoemulsions when introduced into aqueous medium under mild agitation [59]. In 
the human body, the agitation required for formation of nanoemulsions is provided 
by digestive motility of the gastrointestinal tract [34]. In comparison with the ready to 
use nanoemulsions or nanosuspensions, SNEDDS have shown many advantages 
such as: physical or chemical stability profile improvement in long term storage; 
possibility of filling into soft/hard gelatin capsules, which results in attractive 
commercial viability and patient acceptability; no palatability-related issues. 
In recent years, SNEDDS have attracted more and more attention as the mean to 
enhance the oral bioavailability of poorly soluble and highly metabolized drugs. 
Nevertheless, conventional SNEDDS also require a relatively large amount of 
surfactants, which may induce GI irritation and side-effects. In order to achieve a 
safe and efficient delivery system for the poor oral bioavailability drugs, we have 
designed a novel self-nanoemulsifying drug delivery system with high proportion 
lemon essential oil as carrier for lipophilic drugs. 
2.2. Polymer based nanocarriers 
2.2.1. Polymeric nanoparticles  
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Polymeric nanoparticles are submicronic solid particles where drug is 
encapsulated or adsorbed onto particles. With the increasing study on polymers, 
polymeric nanoparticles have emerged as a promising approach in oral drug delivery 
field due to their unique properties such as improved drug stability, the duration of 
the therapeutic effect and to minimize drug degradation and metabolism etc.[3]. A 
variety of biodegradable and biocompatible polymers have been used in the 
research of polymeric nanoparticle preparation include starch, chitosan, poly(lactic 
acid) (PLA), poly(lactic-co-glycolic acid) (PLGA), poly(ε-caprolactone) (PCL), etc. 
[55].  These polymers can be used either separately or combined with each other. 
The advantages of polymeric nanoparticles can be their high stability in the 
gastrointestinal tract, protection and controlled release of the incorporated drugs, 
flexibly modulating, and offering targeting with improved cellular uptake. However, 
the potential challenge for polymeric nanoparticles is associated with the polymer 
toxicity and the residues of organic solvents during the preparation. In addition, 
some of the synthetic polymers are highly hydrophobic and not friendly to hydrophilic 
drugs. These limitations of polymeric nanoparticles should be addressed in the 
future studies.  
2.2.2. Polymeric micelles 
Polymeric micelles are nanosized supramolecular constructs (Figure 1.8) formed 
by amphiphilic molecules consisting of an inner hydrophobic core and an outer 
hydrophilic entity [71]. As a core-shell structure, the hydrophobic core acts a 
reservoir for lipophilic drugs whereas the hydrophilic shell protects the drugs to avoid 
the inactivation and increase the bioavailability and retention.  
Two main methods have been commonly used to produce drug-loaded polymeric 
micelles. Direct dissolution involves dissolving both polymer and drug in an aqueous 
solvent. Alternatively, organic solvents are employed when both polymer and drugs 
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are highly hydrophobic [71]. As reported by literatures, polymeric micelles are stable 
in terms of both thermodynamic and kinetics, imparting overall structural stability. 
Moreover, polymeric micelles allow a multifunctional design to achieve integrated 
diagnostic and therapeutic functions and molecular targeting capabilities [52]. 
Nevertheless, more efforts are still required in order to overcome the challenges, for 
examples, low drug loading, low permeability in transport through intestinal 
membrane.  
 
Figure 1.8 Schematic of polymeric micelles.[52] 
2.2.3. Polymer-drug conjugates 
By definition, polymer-drug conjugates are formed by the conjugation of a 
biocompatible polymeric carrier and low-molecular weight biologically active 
molecule(s) through a biodegradable linker. One of the major differences between 
polymer–drug conjugates and other nanocarriers that contain physically entrapped 
drugs is that the drug molecules are covalently bound to the polymers [72]. Mostly, 
the presence of polymers increases the solubility of hydrophobic drugs, modifies 
drug dispersion profile, extends plasma circulation half-life, and improves its 
pharmacokinetic profile, in turn, enhancing the oral bioavailability of the drugs. On 
the other hand, the biodegradable linker can also become active by triggering drug 
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release under certain conditions, such as a change in pH or in the presence of 
enzymes, such as esterases, lipases or proteases [73].  A pH-sensitive amphiphilic 
dendritic polyrotaxane drug-polymer conjugate by covalently linked doxorubicin 
(DOX) and dendritic polyrotaxane  has been designed and successfully fabricated 
by Yang Kang et al.[74]. This pH-sensitive drug-polymer conjugate showed a 
significantly faster drug release at mildly acidic condition while without burst release 
in aqueous at a physiological pH of 7.4. The results proved that this conjugate has 
tremendous potentials for targeted cancer therapy. 
2.3. Drug nanocrystals  
Besides liposomes, nanocrystals are the most successful nanocarriers when 
considering the first marketed products as well as the total number of commercial 
products and in clinical phases [59]. Nanocrystals are nanosized crystals of pure 
drug particles with the surfactants or polymeric steric stabiliser absorbed onto the 
surface of drugs. Thus, drug nanocrystals possess a 100% drug loading in contrast 
to polymer or lipid-based nanoparticles. As we known, decrease in particle size 
provides a greater surface area in the diffusion layer and leads increase of the drug 
dissolution rate, furthermore, enhancing the absorption (Figure 1.9). Industrially, the 
drug nanocrystals are produced with four main technologies, including top-down (e.g. 
pearl milling, high pressure homogenisation), bottom-up (e.g. precipitation) and 
combination (sonication–precipitation) and chemical approaches.  
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Figure 1.9 Mechanistic representation of absorption via nanocrystals.[24] 
2.4. Dendrimers  
Dendrimers are the new artificial well-defined polymeric nanostructures 
exhibiting tree-like architecture that consist of a hydrophobic central core, branching 
units and terminal functional groups. Dendrimers possess definite molecular weight, 
shape, size and specific physicochemical properties including host–guest 
entrapment properties [24].  Unlike many traditional polymeric nanocarriers, 
dendrimers can be manufactured in almost any size whereas the diameters are 
commonly 10-20nm. In addition, dendrimers also have a narrow polydispersity and 
well defined spherical shape with a variety of terminal functional groups.  These 
unique structural nanosized macromolecules offer multiple ways for incorporation of 
plenty of drugs which pose oral delivery challenges. First, drug molecules can be 
physically encapsulated in the core of the dendrimers. Second, drug molecules can 
be chemically conjugated to the functional end groups on the dendrimer surface 
during or after synthesis. Third, dendrimer drug networks can be formed.  As an 
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approach for the oral bioavailability enhancement, dendrimers provide many 
potential mechanisms. First, the dendrimers entrap the drugs to prevent the drug 
degradation from harsh gastrointestinal tract.  Next, dendrimers may act as 
permeability enhancers and alter the barrier of the intestinal epithelium, thereby 
improve the drug absorption. Last, the dendrimer-drug conjugate may be 
transported across the intestinal epithelium by itself [55]. The properties of 
dendrimers such as size, surface charge and conformation significantly affect the 
drug delivery and absorption in the GIT. Moreover, larger dendrimers have been 
found be more toxic, in comparison with the smaller ones. Conclusively, dendrimers 
are promising delivery system, but more efforts should be required to overcome 
challenging biological barriers. 
2.5. Others 
Except the above mentioned strategies, many other nanotechnologies are also 
employed in the oral drug delivery, for example, carbon nanotubes, silica and silicon 
nanoparticles, nanogels and so on. Carbon nanotubes possess unique hollow 
cylindrical structures, high surface area, conductivity, optical and potential higher 
absorption capabilities, allow the incorporation of drug molecules for controlled and 
site-specific delivery [75].  Silica/silicon nanoparticles offer a high absorption 
capacity, mesoporous channel to change the crystalline state of the drugs and the 
possibility to tailor the physicochemical properties [76]. The biocompatibility, 
chemical properties and mesoporous structure make silica/silicon nanoparticles an 
excellent alternative for drug delivery application. Nanogels are commonly used for 
oral controlled drug delivery with the advantages such as thermodynamic 
compatibility with water, enviro-intelligent, stimuli-sensitive and sustained release. 
3. Self-emulsifying drug delivery systems (SEDDS) 
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3.1. Overview of SEDDS 
3.1.1. Basic concepts 
Self-emulsifying drug delivery systems (SEDDS) are emulsion pre-concentrates or 
anhydrous forms of emulsion. These systems (SEDDS) are ideally isotropic mixtures 
of drugs, oils and surfactants, sometimes containing co-surfactant or co-solvents. 
Upon mild agitation followed by dilution with aqueous media, SEDDS can form fine 
oil-in-water emulsions spontaneously [77]. In gastrointestinal tract of human body, 
the agitation required for formation of emulsions is provided by gastric mobility, the 
aqueous media are gastrointestinal fluids.  In comparison with ready-to-use 
emulsions, which are metastable dispersed forms, SEDDS possess improved 
physical and/or chemical stability profile upon long-term storage, and also easy 
manufacture property. Thus, for the lipophilic drugs that exhibit poor water solubility 
and rate−limited dissolution, SEDDS may offer an improvement in the rate and 
extent of absorption and result in more reproducible blood−time profiles [33].  
3.1.2. Types of SEDDS 
SEDDS include both self-microemulsifying drug delivery systems (SMEDDS) and 
self-nanoemulsifying drug delivery systems (SNEDDS). SMEDDS indicate the 
formulations producing transparent microemulsions with droplets size range 
between 100 and 250 nm while SNEDDS form emulsions with the globule size 
range lower than 100 nm [77]. The term ‘droplet’ is used to describe micelles, mixed 
micelles which exist in the emulsions. In details, the microemulsion is a 
thermodynamically stable colloidal dispersion consisting of small spheroid particles 
(comprised of oil, surfactant, and possibly co-surfactant) dispersed within an 
aqueous medium and thus in equilibrium. In contrast, the nanoemulsion is non-
equilibrium colloidal dispersion system that over time spontaneously will exhibit 
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coalescence of the dispersed droplets [78, 79]. However, nanoemulsions can have a 
relatively high kinetic stability, and in this case it will be difficult to distinguish on the 
previous basis micro and nano-emulsions [79]. Actually, the structure of the droplet 
in both nanoemulsion and microemulsion are very similar: the non-polar tails of 
surfactant molecules protrude into the lipophilic core formed by the oil, while the 
polar head groups protrude into the surrounding aqueous phase (Figure 1.10). 
 
Figure 1.10 Schematic of microemulsions droplet and nanoemulsions droplet formed 
from oil, water and surfactant [78]. 
3.1.3. Advantages of SEDDS 
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Self-emulsifying drug delivery systems are new approach for enhancing the oral 
bioavailability of lipophilic drugs. They offer a number of advantages over the 
conventional micro/nanoemulsions systems owing to their interesting properties.  
Potential advantages of SEDDS include:  
Long-term stability    
As anhydrous formulations, SEDDS possess the improved physicochemical 
stability profile upon long-term storage in contrast with nanoemulsions that contain 
water; 
Patient compliance     
The SEDDS formulations can be filled into unit dosage forms, such as soft/hard 
gelatin capsules, which improves patient acceptability and commercial viability [80]; 
Palatability    
No palatability-related issues in comparison with other formulations/tablets, as 
SEDDS formulations can be filled into capsules [80]; 
Ease of manufacture & scale-up    
Ease of manufacture and scale-up are key factors that govern success in its 
industrial applicability. The methods employed for the fabrication of SEDDS 
formulations, such as simple mixed with an agitator and volumetric liquid filling 
equipment, offer easy manufacture at large-scale and economic benefits as well; 
Quick onset of action     
Quick onset of action is required in many conditions, such as inflammation, 
hypertension and angina [34, 80]. SEDDS have capacity to enhance the oral 
absorption of the drugs, which would result in quick onset of actions. Study from 
Taha et al.[81] showed that the tmax (tmax is the term used to describe the time at 
which the maximum plasma concentration of a drug after administration is observed.) 
is reduced considerably when comparing the pharmacokinetic analysis of SEDDS 
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and conventional formulation without any additives. Many other literatures can be 
found which reflect the potential of SNEDDS to increase the bioavailability of drug; 
Reduction in the drug dose 
SEDDS offer improved drug-loading capacity and oral bioavailability or therapeutic 
effect for numerous hydrophobic drugs owing to the drug solubility in excipients. The 
enhancement in drug-loading and bioavailability can be translated into reduction in 
the drug dose and dose-related side effects of many hydrophobic drugs. 
3.1.4. Limitations of SEDDS 
Each strategy has specific advantages and limitations. Limitations of SEDDS are: 
 High content of surfactant in the SEDDS formulation may irritate 
gastrointestinal tract and result in toxicity. This problem can be solved by 
designing and optimizing SEDDS with decreased amount of surfactants. 
 There is no effective in vitro model for the assessment of the SEDDS 
formulation [82]. 
 Presence of high amount of surfactant or co-solvent may cause the 
degradation and instability of the drugs [83]. 
 Soft gel or hard gel capsule must be sealed effectively, due to the possibility 
of component loss and leak. 
 In addition, SEDDS are not very suitable for controlled drug release. 
3.2. Formulation of SEDDS 
3.2.1. Excipients screening for SEDDS 
With plenty of liquid excipients available, ranging from oils through biological 
lipids and hydrophobic and hydrophilic surfactants to water-soluble co-surfactant/ 
co-solvents, there are various combinations that could form colloidal emulsions [77, 
84]. Pharmaceutical acceptability and toxicity issues of the excipients used make the 
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screening of excipients really critical. Hence, it is essential to optimize the quantities 
of the SEDDS components at the initial selection. Self-emulsification has been 
shown to be specific to the nature and amount of the components; the ratio of 
oil/surfactant; and the temperature at which self-emulsification occurs [85, 86]. 
Supporting these facts, only a few of specific pharmaceutical excipient combinations 
could form fine self-emulsifying systems. The following points should be considered 
in the SEDDS excipients selection: 
(I) Drug solubility in different oil, surfactants and co-surfactant/ 
co-solvents;  
(II) The final selection of oil, surfactant and co-surfactant/co-
solvent based on solubility studies and the preparation of the ternary 
phase diagrams [77].  
These excipients are discussed below. 
Oil phase 
Oil is the most important excipient which can solubilize the lipophilic drug in a 
specific amount. Unmodified edible oils provide the most natural basis as lipid 
vehicles, but their poor lipophilic drug dissolution and their relative difficulty in 
efficient self-emulsification markedly reduce their use [87]. Long chain triglyceride 
and medium chain triglyceride oils with different degrees of saturation have been 
used in the design of SEDDS. Hydrolysed or modified vegetable oils have 
contributed widely to the success of SEDDS because of their biocompatibility and 
physiological advantages. 
Surfactant 
Surfactants with amphiphilic character help the solubilisation of lipophilic drugs 
so preventing their precipitation in the gastrointestinal lumen.  Non-ionic surfactants 
are frequently selected for fabrication of SEDDS due to their less toxicity and 
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because typically possess low critical micelle concentration, in comparison with their 
ionic surfactants [87]. Non-ionic surfactants possessing high HLB value are widely 
employed for the immediate formation of o/w droplets and/or rapid spreading of the 
formulation in the aqueous phase, providing a good self-emulsifying performance 
[88]. 
Co-surfactant 
Stable interfacial tension is rarely achieved by the use of single surfactants, 
usually necessitating the addition of a co-surfactant. The presence of a co-surfactant 
decreases the bending stress of interface and allows the interfacial film sufficient 
flexibility to take up different curvatures required to form nanoemulsions over a wide 
range of composition [89].  
Aqueous phase 
The droplet size, stability and performance of emulsion formed from SEDDS 
formulations is influenced by the nature of the aqueous environment where 
formulations would be introduced. Therefore, pH and ionic content of the aqueous 
phase should be accurately considered in the SEDDS designing [34]. The 
physiological environment has pH ranges varying from pH 1.2 (pH in stomach) to 7.4 
and greater (pH of blood and intestine). In addition, the presence of various ions in 
the GIT significantly affects the properties of nanoemulsions generated from SEDDS 
[34]. 
3.2.2. Mechanism of SEDDS 
The mechanism by which self-emulsification takes place is not yet well understood. 
Nevetheless,  it has been suggested by Reiss et al [90] that self-emulsification 
occurs when the entropy change favoring dispersion is greater than the energy 
required to increase the surface area of the dispersion. The free energy of emulsion 
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formulation is a direct function of the energy required to create a new surface 
between the oil and water phases and can be described by 
 
∆G = ∑ (𝑁𝑖4𝜋𝑟𝑖
2𝜎)𝑖     [91]  
Where 
∆G ---  the free energy associated with the process (ignoring the free energy of 
mixing);  
N --- the number of droplets of radius r and s is the interfacial energy; 
𝑟 --- the radius of globules; 
𝜎 ---  the interfacial energy. 
The two formed phases of the emulsion will tend to separate with time to reduce 
the interfacial energy and thus reduce the free energy of the system. The 
conventional emulsifying agents stabilize emulsions, reduce the interfacial energy by 
forming a monolayer around the emulsion droplets, and in turn, provide a barrier to 
coalescence.  In this case, the separation of the two phases is merely being delayed 
as these emulsions are still thermodynamically unstable. Emulsification requiring 
very little input energy involves destabilization through contraction of local interfacial 
regions. It is necessary for the interfacial structure to show no resistance against 
surface shearing in order for emulsification to take place [86]. The potential 
mechanisms responsible for improvement in oral bioavailability by self-
nanoemulsifying drug delivery system are elucidated in Figure 1.11. 
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Figure 1.11 Mechanisms of self-nanoemulsifying drug delivery systems to improve 
bioavailability. [92] 
3.2.3. The factors influencing the phenomenon of SEDDS 
A thorough understanding of the spontaneous nanoemulsification process and 
physicochemical and biopharmaceutical properties of components used for the 
fabrication of SEDDS would be of great help for developing successful formulations 
of SEDDS.   
The factors influencing the formation of SEDDS can be summarized as following:  
 The physicochemical nature and concentration of oily phase, surfactant and 
cosurfactant; 
 The ratio of the excipients, especially the ratio of oil and surfactant; 
 The temperature, pH and ionic content of the aqueous phase where 
nanoemulsification would occur; 
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 Physicochemical properties of the drug, such as hydrophilicity/lipophilicity, pKa. 
and polarity [34]. 
3.3. Characterization of SEDDS 
3.3.1. Ternary phase diagrams 
Construction of ternary or pseudo-ternary phase diagrams is usually employed in 
the development of SEDDS. Ternary phase diagrams enable comparison of different 
surfactants and their synergistic effect with co-surfactant. They can also help to 
determine the optimum concentration ranges of different excipients and  to identify 
the self-emulsification regions. The boundaries of different phase regions can easily 
be assessed visually. 
3.3.2. Emulsification time 
With the purpose of quantifying the efficiency of emulsification of SEDDS. Pouton 
[93] employed the rotating paddle to promote emulsification in a crude nephelometer. 
This enabled an estimation of the time taken for emulsification. On completion of 
emulsification, the SEDDS samples were taken for particle sizing by photon 
correlation spectroscopy, and further by other characterizations. 
3.3.3. Turbidity measurement 
 The turbidity measurements can be carried out to identify the efficient self-
emulsification by establishing whether the dispersion reaches equilibrium rapidly and 
in a reproducible time [94]. These measurements are commonly carried out on 
turbidity meters, and also can be processed in terms of spectroscopic 
characterization of optical clarity (i.e. absorbance of suitably diluted aqueous 
dispersion at 400 nm) [95]. 
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3.3.4. Droplet size 
Droplet size is a decisive factor in self-emulsification performance because it will 
determine the rate and extent of drug release, as well as the stability of the emulsion 
[80]. Dynamic light scattering (DLS) techniques, photon correlation spectroscopy 
and microscopic techniques are mainly used for the determination of the emulsion 
droplet size. DLS is ideal for measuring particles or droplets in the diameter of 3 nm 
to 3 mm. Droplet size distributions can be further verified by cryogenic transmission 
electron microscopy (cryo-TEM), which offers the possibility to observe the droplet’s 
size and shape. 
3.3.5. Zeta potential 
Zeta potential is used to identify the charge of the oil droplets of SEDDS. The 
charge of the oil droplets in conventional SEDDS is negative due to the presence of 
free fatty acids [96]. For the droplets in SEDDS emulsions, a high zeta potential will 
confer stability and long shelf life. When the potential is low, attractive forces may 
exceed this repulsion and the emulsion may break and aggregate. Some 
investigators consider zeta potential as secondary characterization parameter for 
SEDDS, because SEDDS are preconcentrate mixture of drug in oil and surfactant 
and emulsified in vivo only. The zeta potential of SEDDS emulsion is commonly 
investigated using Malvern ZetaSizer [86]. 
3.3.6. Morphology  
The morphology of the nanoemulsion droplets can be evaluated by Cryo-
Transmission Electron Microscopy (Cryo-TEM), small-angle neutron scattering and 
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small-angle X-ray scattering. Cryo-TEM and small-angle neutron scattering offer the 
advantage of vizualising the particle sizes and shapes. Furthermore, droplets size 
distributions can be further verified by cryo-TEM. Small-angle X-ray scattering is 
used to determine the microscale or nanoscale structure of particle systems in terms 
of such parameters as averaged particle sizes, shapes, distribution and surface-to-
volume ratio [77]. 
3.3.7. Viscosity.  
The rheological properties of the SEDDS formulations are useful to assess their 
ability to be filled in the soft or hard gelatin capsules. The viscosity of formulations 
should not be high to create problem in pourability. Conversely, low viscosity may 
lead to leakage from the capsules. 
3.4. Dosage Forms from SEDDS 
SEDDS are usually limited by liquid dosage forms, because many excipients used 
in SEDDS are not solid at room temperature. In view of the advantages and 
limitations of SEDDS, various dosage forms of SEDDS have been extensively 
exploited in recent years, as they frequently represent more effective alternatives to 
conventional liquid SEDDS. 
3.4.1. Dry emulsions 
Dry emulsion formulations are typically prepared from oil in water (O/W) 
emulsions containing a solid carrier in the aqueous phase by freeze-drying, spray 
drying or rotary evaporation. The dry emulsions spontaneously disperse in vivo or 
when exposed to an aqueous solution. Dry emulsions can be used for further 
preparation of capsules and tablets. [32]. A exciting finding in this field is the newly 
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developed enteric-coated dry emulsion formulation, which is potentially applicable 
for the oral delivery of peptide and protein drugs [97]. 
3.4.2. Self-emulsifying sustained/controlled-release tablets 
In order to greatly reduce the amount of solidifying excipients required for 
transformation of SEDDS into solid dosage forms, Patil et al [98] developed a gelled 
SEDDS. The patent diclosed by Schwarz et al [99] showed that  SE tablets are of 
great utility in obviating adverse effect. Inclusion of indomethacin into self-
emulsifying tablets could increase the penetration efficiency through the 
gastrointestinal mucosal membranes, potentially reducing gastrointestinal bleeding. 
The newest improvement in the field of self-emulsifying tablet is the self-emulsifying 
osmotic pump tablet, where the elementary osmotic pump system was the carrier of 
the self-emulsifying tablet [32]. 
3.4.3. Self-emulsifying suppositories 
Some investigators proved that Solid-SEDDS could increase not only 
gastrointestinal adsorption but also rectal/vaginal adsorption [100] . Glycyrrhizin, 
which barely achieves therapeutic plasma concentrations by the oral route, can 
obtain fine therapeutic levels for chronic hepatic diseases by either vaginal or rectal 
self-emulsifying suppositories [32]. 
3.4.4. Self-emulsifying implants 
Researches on self-emulsifying implants have signifacantly improved the utility 
and application of solid-SEDDS. Carmustine (BCNU) is a chemotherapeutic agent 
used to treat malignant brain tumours. However, its short half life hinders its 
therapeutic efficacy. In order to enhance its stability and intestinal permeablity, a 
self-emulsifying system of carmustine was designed and fabricated into wafers with 
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flat and smooth surface by compression molding. The results demonstrated that the 
self-emulsifying system increased the in vitro half-life of BCNU up to 130 min 
compared with 45 min of intact BCNU. The in vitro release of BCNU from self-
emulsifying PLGA wafers was prolonged to 7 days [101]. 
4. Oral controlled drug delivery systems 
4.1. Overview of oral controlled drug delivery systems 
4.1.1. Historical perspective 
Controlled drug delivery technology has progressed for more than 60 years. This 
progression began in 1952 with the introduction of the first sustained release 
formulation. In the years 1950-80, a first generation (1G) of sustained drug delivery 
system was developed for oral and transdermal sustained release, while during 
1980–2010 a second generation (2G) comprised the development of zero-order 
release systems, self-regulated drug delivery systems, long-term depot formulations, 
and nanotechnology-based delivery systems [102].  A third generation (3G) of drug 
delivery systems is excepted to develop drug delivery formulations primarily based 
on today's necessities, and focus on understanding the biological barriers. Figure 
1.12 describes the three generations of drug delivery systems.  
Controlled drug delivery systems were developed to increase patient compliance 
and acceptability. Years ago it was common to take a drug 4 and more times a day 
by oral administration. Making the drug administration once/twice-a-day resulted in 
dramatic improvement in patient convenience and compliance. Benefit for the 
patient, drug effectiveness and better compliance are the main advantages of 
controlled drug delivery systems. Moreover, the introduction of novel administration 
or release methods rendered old drugs again effective and useful [103].  
Delayed release, sustained release, and repeat action formulations are the three 
most common controlled release formulations [104, 105]. A common example of 
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delayed release is the enteric formulation of  tablets or capsules [106], in which drug 
will not be released in gastric fluid (harsh acidic environment), and will remain 
protected until it reaches the intestine (neutral environment). In sustained release 
formulations, a portion of drug is released immediately, and the remaining drug is 
released slowly over an extended period of time. In fixed dosage combination (FDC), 
combination of immediate release (IR) and sustained release (SR) for single drug or 
double drugs are used[107, 108]. 
 
 
Figure 1.12  Evolution of controlled drug delivery systems since 1950. [102] 
4.1.2. Limiting factors for oral controlled drug delivery formulations  
There are a few unique properties of the gastrointestinal tract (GIT) that make 
development of oral controlled drug delivery rather difficult. These limiting factors 
and disadvantages can be classified into: 
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(1) Relatively short gastric emptying and intestinal transit time [109]; 
(2) Nonuniform absorption abilities of different segments of GIT [110]; 
(3) Pre-systemic clearance [111] ; 
(4) Poor absorption of peptide and protein drugs [112]; 
(5) Difficult in vitro–in vivo correlations; 
(6) Higher cost of some controlled drug delivery formulations [113].  
4.2. Classification and mechanisms of oral controlled drug delivery systems 
In general, for most of the pharmaceutical industry, drug delivery has induced 
simple, fast-acting responses (conventional forms) via oral or injection delivery 
routes. Problems include reduced potencies because of partial degradation (first 
pass metabolism), toxic levels of administration (in cases of excess dose), increased 
costs associated with excess dosing, and compliance issues due to administration 
pain [113]. A useful classification of current controlled release drug delivery systems 
based on mechanistic considerations will be outlined below [114]. This classification 
provides a systematic account of principles behind the design of various oral 
controlled release products. 
4.2.1. Membrane Systems 
Membrane systems, by virtue of its rate controlling membrane, are generally non-
disintegrating. Products are usually developed like drug core surrounded by a rate 
controlling membrane (e.g., microcapsules, coated pellets, beads, or coated tablets). 
Drug release from membrane systems is generally controlled by osmotic pumping or 
solution–diffusion mechanism. The osmotic-controlled drug release (OROS™) 
concept for controlling delivery is based on dissolved drug being transported in a 
controlled manner from the dosage form to the external media under the influence of 
osmotic pressure [115]. Dissolution-controlled release can be obtained by slowing 
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the dissolution rate of a drug in the gastrointestinal medium, by incorporating the 
drug with insoluble polymer, and coating drug particles/ granules with polymeric 
materials of varying thicknesses [116]. The rate-limiting step for the dissolution of 
drug is the diffusion across the aqueous boundary layer [19]. 
4.2.2. Matrix Systems 
Matrix systems are actually introduced by drug dissolved or dispersed in a carrier 
matrix (e.g., beads, pellets, or tablets). Drug release from matrix type products are 
mostly regulated by mechanisms such as (1) diffusion, (2) swelling/erosion, (3) 
geometry/area changes, and (4) nonuniform drug distribution. A good example of 
marketed pulsatile product is Drixoral Cold & Allergy Sustained-Action Tablets 
(pseudoephedrine sulfate and dexbrompheniramine maleate; Schering-Plough) that 
produce two pulses of drug release separated by several hours [19, 117]. 
4.2.3. Hybrid Systems 
Hybrid systems comnmonly are the combinations of membrane and matrix 
systems (e.g., coated pellets or beads embedded in a tablet matrix,core press 
coated tablets, or tablets in a capsule). Hybrid systems can be disintegrating or 
nondisintegrating. Hybrid chronotherapeutic dosage forms have been designed 
based on osmotically controlled-release, membrane-coated beads (delayed release), 
press-coated tablets, or the combination of erodible polymer coating and a drug 
matrix (e.g., beads, pellets, and tablets) [118]. Typical chronotherapeutic product 
examples include Covera-HS (verapamil HCl; Pfizer), Verelan PM (verapamil HCl; 
Schwarz), and InnoPran XL (propranolol HCl; Reliant) [19]. All of these systems can 
be in either single-unit or multiple-unit dosage forms. 
4.3. Preformation consideration for controlled release formulations 
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4.3.1. Particulate and mechanical properties’ consideration for drug 
substances  
The physicochemical properties of drug substances have a large impact on the 
selection of controlled release formulations and manufacturing process. The drug’s 
physicochemical properties to be considered include molecular size, lipophilicity, 
solubility, protein binding, polar surface area, and charge or rotatable bonds. These 
properties will ultimately influence the permeability of a compound across the lung 
epithelial barrier [113].  
4.3.2. Stability and compatibility 
A drug substance is usually more stable by itself than in a formulation with 
excipients, and as the drug concentration decreases, the stability deteriorates in a 
corresponding manner. A forced degradation study encompasses a comprehensive 
assessment of degradation under various stress conditions including acid, base, 
heat, light, and oxidative conditions which is necessary to demonstrate the stability 
of the drug substances. Furthermore, pH–stability profile and stabilization are 
especially useful for controlled release dosage forms since the drug is retained in a 
matrix or within coating membranes together with a pH modifier. In vitro pH-stability 
studies may help predict performance in first-time in human studies. 
 Besides aboved mentions, compatibility of excipient and drug is very important 
parameter for the formation of controlled drug delivery systems. Despite the 
importance of drug–excipient interaction, no standard method is generally accepted 
among pharmaceutical scientists and most methods reported in the literature have 
poor predictive values [119]. 
4.3.3. Solubility consideration 
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Solubility of the drug substance is a fundamental property that should be 
evaluated early in the development of controlled release dosage forms. In reality, it 
is difficult to predict the aqueous solubility due to the complicated solubilization 
procedure and solid-phase chemistry of the drug candidates [120]. A variety of 
approaches are employed at different phases of drug discovery and development 
such as in silico, kinetic and equilibrium solubility. A lack of solubility affects the 
ability of drug to achieve efficacious and toxicologically relevant exposures in 
animals [120].  For drugs with high solubility, dissolution rate can be slowed down by 
embedding the drug in a matrix or enclosing the drug within a film, whereas for 
drugs with low solubility, it is more difficult to shift the controlling mechanism from 
solubility to formulation [19]. 
4.4. Lipids in oral controlled release drug delivery 
4.4.1. Lipids in oral drug delivery 
   Lipids not only vary in structures and physiochemical properties, but also in their 
digestibility and absorption pathway,  therefore,  selection of lipid excipients and 
dosage form has a pronounced effect on the biopharmaceutical aspects of drug 
absorption and distribution both in vitro and in vivo [121]. In particular, the following 
properties and behaviors of lipids can play key roles: 
 Lipids may have amphiphilic structures that determine their capability to self-
assemble in aqueous environments. Such behavior can have a critical effect on 
drug disposition kinetics in the gastrointestinal tract [115].  
 Lipids can act as solvents, leading to drug being present in the gastrointestinal 
fluids thereby overcoming the drug dissolution step [122].  
50 
 
 Lipids may be digestible. Digestion of dietary and formulation lipids can lead to 
generation of colloidal structures in the GIT, providing transient solubilization of 
drug, and reducing the propensity for precipitation prior to absorption. 
4.4.2. Mechanisms of controlled release using lipids 
The mechanisms of controlled release can be summarized as follows, matrix 
controlled release; gastroretention; stimulation of lymphatic transport.   
Matrix plays as a barrier to slow the appearance of dissolved drug in 
gastrointestinal fluids, by inhibiting diffusion , or by requiring erosion of the matrix 
before exposure of undissolved drug particles [115]. Gastroretention strategies aim 
to retain the dosage form in the stomach, preventing transit before complete drug 
release. Prolonged retention coupled with slow drug release can prolong drug 
absorption and therapeutic effect. Drug transport via lymph is increased with 
increasing amounts of co-administered long-chain lipids swelling the chylomicrons 
and providing a greater pool for drugs to directly entrter systemic circulation. Such 
lymphatic transport avoids hepatic first-pass metabolism experienced by drug 
molecules transported via the portal blood system [115]. 
4.4.3. Technologies for controlled release using lipids 
Lipid-based formulations range from simple lipid solutions to complex systems 
incorporating triglycerides, partially digested triglycerides, semisynthetic ester 
glycerides, lipophilic and hydrophilic surfactants and cosolvents [123, 124]. The 
formulation can influence digestibility, dispersion and solubilization of the lipid 
vehicle in vivo, in turn, influencing drug absorption. Solid lipid particles are 
composed of melt-emulsified lipids, which are solid nature. They offer the 
advantages of avoidance of organic solvents, resulting in a comparatively stable 
system with protective effects against serious drug toxicity [125]. Slow erosion of the 
51 
 
lipid controls drug release, prolonging plasma residence and inhibit peak plasma 
concentrations. In vitro release is slowed in comparison to other formulations [126, 
127].   
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Chapter II Objectives and outline 
Self-emulsifying drug delivery systems (SEDDS) represent a vital tool in 
enhancing oral bioavailability of lipophilic drugs. Lipophilic drugs can be dissolved in 
SEDDS formulations, enabling them to be administered as a unit dosage form for 
oral administration. 
The overall objective of the present thesis was to improve the solubility, 
dissolution rate, potentially the intestinal permeability and bioabavailability of l of 
lipophilic drugs by using self-nanoemulsifying drug delivery systems (SNEDDS) for 
oral administration. 
The main objective implies the following specific objectives: 
1. Design and optimization of novel self-nanoemulsifying drug delivery systems 
(SNEDDS) with a high proportion of essential oil as carrier. 
Surfactants are indispensable  component for self-emulsifying formulations. 
However, usage of large amount of surfactants would induce irritation to 
gastrointestinal tract (GIT) and moreover toxicity. A compromise must be 
reached between the surfactant toxicity and self-emulsifying capacity of the 
formulation.   
In our work, essential oil was using to replace part of the surfactant for 
reducing the potential toxicity of the formulation. As will be shown, our high 
essential oil containing SNEDDS formulations possess excellent self-
emulsfiying property, stability and suitable in vitro drug release profile, while 
the drug loading capacity didn’t decrease. 
2. Development of a pH-sensitive self-emulsifying formulation (pH-SNEDDS) to 
avoid the release of the drug in the stomach and protect it from its harsh 
acidic environment, that is paticularly important for acid-labile lipophilic drugs. 
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Orally administered bioactive compounds have to resist the harsh acidic fluids 
or enzyme digestion in stomach, in order to reach their absorbed destination in 
small intestine. The use of pH-sensitive self-nanoemulsifying drug delivery 
systems (pH-SNEDDS) could overcome the drug degradation in the stomach 
while enhancing drug solubility and dissolution rate.  Our in vitro characterization 
studies showed that pH-SNEDDS would protect the acid-labile drug from harsh 
acidic gastric-like fluids while providing excellent self-emulsification in the 
intestinaldtract. 
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Chapter III Design and optimization of self-nanoemulsifying formulations for 
lipophilic drugs 
 
The purpose of the current study was to develop and optimize novel self-
nanoemulsifying drug delivery systems (SNEDDS) with a high proportion of 
essential oil as carriers for lipophilic drugs. Solubility and droplet size as a function 
of the composition were investigated, and a ternary phase diagram was constructed 
in order to identify the self-emulsification regions. The optimized SNEDDS 
formulation consisted of lemon essential oil (oil), Cremophor RH40 (surfactant) and 
Transcutol HP (co-surfactant) in the ratio 50:30:20 (v/v). Ibuprofen was chosen as 
the model drug. The droplet size, ζ-potential and stability of the drug-loaded 
optimized formulations were determined. The stability of SNEDDS was proved after 
triple freezing/ thawing cycles and storage at 4 °C and 25 °C for 3 months. In vitro 
drug release studies of optimized SNEDDS revealed a significant increase of the 
drug release and release rate in comparison to the Ibuprofen suspension (80% 
versus approximately 40% in 2 h). The results indicated that these SNEDDS 
formulations could be used to improve the bioavailability of lipophilic drugs. 
 
1. Introduction 
Various approaches have been proposed to increase dissolution and 
bioavailability of lipophilic drugs [1-3]; among those, the use of self-emulsifying drug 
delivery systems has been suggested [4, 5]. Self-emulsifying drug delivery systems 
(SEDDS) are defined as isotropic mixtures of oil, a surfactant, a co-surfactant and a 
drug which can rapidly form fine oil-in-water emulsions upon mild agitation in an 
aqueous media [6]. Depending on the droplet size, SEDDS can be categorized as 
self-microemulsifying drug delivery systems (SMEDDS, droplet size range between 
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100 and 250 nm) and self-nanoemulsifying drug delivery systems (SNEDDS, 
droplets smaller than 100 nm) [7]. The larger interfacial area of SNEDDS improves 
the efficiency of drug release and absorption, resulting in the decrease of drug 
dosage and administration frequency [8]. Moreover, SNEDDS would protect the 
drug from the enzymes of the GI and reduce the first-pass effect [6]. 
Considering the advantages of SNEDDS and the shortages of previous research, 
in the present chapter, a novel high essential-oil-contained self-nanoemulsifying 
drug delivery system was carefully investigated with the aim of enhancing the 
solubility and dissolution of lipophilic drugs. Figure 3.1 demonstrates the human 
digestive tract with self-nanoemulsifying drug delivery system. 
 
Figure 3.1 Schematic outline of the human digestive tract with self-nanoemulsifying 
drug delivery system. 
 
Large amount of surfactants would induce irritation to the gastrointestinal system, 
thus requiring a balance between the surfactant toxicity and self-emulsifying 
capacity of the formulation [9]. The optimization of SNEDDS was performed in terms 
of solubility, droplet size, drug loading and in vitro drug release. 
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Ibuprofen, an anti-inflammatory drug belonging to class II of the biopharmaceutical 
classification [4, 10, 11] that is poorly soluble in acid solutions, such as gastric fluid 
(21 mg l
−1
 at pH 1.2) [4, 10, 11], was chosen as the model drug (Figure 3.2). 
 
Figure 3.2 Molecular structure of ibuprofen. 
2. Materials and methods 
2.1. Materials 
Ibuprofen, lemon essential oil, anise essential oil, castor essential oil, soybean oil, 
Span80 and Cremophor RH40 were purchased from Sigma-Aldrich (Milan, Italy). 
The Labrasol, Labrafil M 1944CS, Labrafil M 2125CS, Capryol 90 and Transcutol 
HP were received as free samples from Gattefosse (Saint-Priest, France). The 
Capmul MCM C8 EP was obtained from ABITEC Corporation (Janesville, USA). The 
acetonitrile and methanol (analytical reagent grade) were purchased from Sigma-
Aldrich (Milan, Italy). Deionized water was used through the whole study. 
2.2. Drug solubility 
  The solubility of Ibuprofen in various oils, surfactants and cosurfactants was 
analyzed by high performance liquid chromatography (HPLC). The excess amount 
of Ibuprofen (approximately 500 mg) was added to a 2 ml sealed vial containing 1 ml 
of each selected oil, surfactant or co-surfactant. The mixture was vortex-mixed, then 
stirred in a shaking water bath at 38.0 ± 0.5 ℃ for 48 h to facilitate the dissolution 
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and was finally centrifuged at 3000 g for 15 min with a SIGMA 2-16 Centrifuge 
(SIGMA Laborzentrifugen GmbH, Osterode am Harz, Germany). The aliquots of the 
supernatant were filtered using a 0.2 μm PTFE filter membrane to remove the 
undissolved Ibuprofen. The filtrates were diluted with a mobile phase (acetonitrile: 
methanol (6:4 v v−1) with 4 g L−1 of chloroacetic acid, adjusted to a pH of 3.0 with 
ammonium hydroxide) and analyzed by HPLC (column Kinetex C18 100A, working 
temperature of 30 ℃, flow rate of 1 ml min−1 with a 20 μl injection volume, Jasco 
intelligent UV-1570, Jasco Corporation, Japan). The assays were repeated in 
triplicate; the mean and standard deviation (σ) were calculated. 
2.3. Surfactant and oil miscibility 
The oil and surfactant in the ratio of 1:1 were shaken at 40 °C in 3 ml transparent 
glass vials. The miscibility was monitored optically and considered to be good when 
the mixture was transparent. 
2.4. Construction of ternary phase diagrams 
Ternary phase diagrams of the selected oils, surfactants and co-surfactants at 
various proportions were constructed to identify the self-emulsification regions. A 
total of 54 formulations were investigated with various proportions of oil, surfactant 
and co-surfactant for each system. The self-emulsification was observed using the 
modified visual examination method reported by Villar et al [12]. Briefly, 200 μl 
formulations were added drop by drop to 500 ml deionized water or simulated 
gastric fluid (0.01 M HCl solution) at 38.0 ± 0.5 ℃; the mixtures were gently stirred 
with a magnetic bar to simulate the gastrointestinal wriggle and were observed to 
classify the emulsifying property. The mixtures were considered well dispersed when 
the formulation spread quickly in water and was clear or milk-white color with no 
phase separation or coalescence after the stirring stopped (Figure 3.3). Four 
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formulations are showed in Figure 3.4, panels A and B correspond with self-
nanoemulsifying systems showing “Good” emulsification capacity, in contrast with 
panels C and D show systems with “Bad” emulsification capacity [12]. All the 
measurements were repeated three times. The ternary phase diagrams were 
constructed using Origin software (OriginLab Corporation, USA). 
 
Figure 3.3 Set-up for preparation of nanoemulsions by the self-emulsification 
method. 
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Figure 3.4 Formulations classified as “Good” for emulsifying ability (A and B) and 
formulations classified as “Bad” for emulsifying ability (C and D) [12]. 
2.5. Droplet size 
The droplet size was determined through dynamic light scattering (Zetasizer 
Nano-ZS, Malvern Instruments, Worcestershire, UK) at a scattering angle of 90° at 
25 ℃. All the SNEDDS emulsions were diluted five times with deionized water in a 
disposable cuvette, and the content was gently mixed. The average droplet size and 
polydispersity index (PDI) were calculated. Three consecutive measurements for 
each sample were made, and the results were presented as the mean and standard 
deviation. 
2.6. Optimization and characterization of Ibuprofen-loaded SNEDDS 
2.6.1. Solubility in optimized formulations 
The solubility of Ibuprofen in optimized formulations was evaluated as in section 
2.2. The concentrations were detected at the wavelength of 264 nm where there 
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was no UV light absorption of the other components. The assays were repeated in 
triplicate, and the results were represented as the mean and standard deviation. 
2.6.2. Evaluation of viscosity 
The viscosity of each ibuprofen-loaded formulations were measured by Physica 
MCR 301(Anton Paar, Graz, Austrian) at 25±0.5 ℃  in triplicate. Samples were 
formulated 12 h before the measurements for purpose of stabilization. 1-2 ml sample 
was put on the plate and equilibrated for analysis. Measurements were performed at 
shear rates from 0 to 100 s
−1
. 
2.6.3. Self-emulsification time and appearance 
Followed the process of emulsification, visual observation was used to determine 
the self-emulsification time for each SNEDDS emulsion. Begin timing after the 
formulation was added completely, and stop until the homogenous emulsion was 
formulated. The appearance of emulsions was monitored and categorize as: clear, 
translucence and cloudy. 
2.6.4. Droplet size and ζ-potential measurements 
The droplet size and ζ-potential measurements were performed at 25 ℃ with a 
Zetasizer Nano-ZS dynamic light scattering apparatus (Malvern Instruments, 
Worcestershire, UK), as in paragraph 2.5. 
2.6.5. Formulation stability 
Selected Ibuprofen-loaded formulations underwent three consecutive freezing-
thawing cycles to assess their stability. Each cycle consisted of freezing the 
formulation at 4 ℃ for 24 hours in the refrigerator, followed by heating at 65 ℃ for 48 
hours in an incubator. The droplet size, PDI and ζ-potential of the emulsions were 
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determined after each cycle, and moreover every month on formulations stored at 4 ℃ 
and 25 ℃ for up to three months. 
2.6.6. Morphological characterization 
The morphology of the optimal Ibuprofen-loaded SNEDDS was assessed by TEM 
(Philips CM12 microscope operating at 120 kV). The SNEDDS emulsion was diluted 
100 times with 0.01 M HCL solution (simulated gastric fluid) and mixed by gently 
shaking. One drop of diluted emulsion was placed on the TEM copper grids; we 
removed the excess liquid with a filter paper and placed them in a hood until 
complete drying. Subsequently, the grid was stained with a 2% phosphotungstic acid 
solution for 30 seconds. 
2.6.7. In vitro drug release study 
For the in vitro release studies, a dialysis membrane tubing (MWCO: 3500 Da, 
Spectrum®) was soaked in deionized water for 24 h before use. 2 ml of Ibuprofen-
loaded SNEDDS emulsion (containing 30 mg Ibuprofen) and 2 ml Ibuprofen 
suspension (30 mg Ibuprofen in phosphate-buffered saline as the control) were 
sealed in dialysis tubings suspended in glass beakers containing 500 mL of 
simulated gastric fluid (0.01 M HCl solution) or simulated intestinal fluid (phosphate 
buffer saline, pH 6.8, SIGMA) as the release medium, magnetically stirred at 100 
rpm at 38 ± 0.5 ℃, as shown in Figure 3.5. 2 ml of aliquot were periodically taken, 
replaced with an equal amount of fresh release medium and filtered through a 0.2 
μm PTFE membrane filter. The content of the drug was analyzed by HPLC. 
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Figure 3.5 Schematic models illustrating the in vitro drug release study. 
2.7. Statistics 
The statistical analysis was performed using GraphPad Prism software 
(GraphPad Software Inc., California, USA). An one-way analysis of variance 
(ANOVA) was carried out on the results. 
3. Results and discussion 
3.1. Solubility of Ibuprofen in various vehicles 
The drug-loading capacity of the SNEDDS formulations depends on the solubility 
of Ibuprofen in the various vehicles of the system, which was determined by 
solubility studies. The results are presented in Figure 3.6. Among the four oils that 
have been tested, Ibuprofen has similar solubility in anise essential oil and lemon 
essential oil (about 120 mg ml
−1
), which is better than castor essential oil and 
soybean oil (about 90 mg ml
−1
). Surfactant has a pivotal role in stabilizing 
nanoemulsions, its nature and amount determining droplet size and stability [13]. 
Nonionic surfactants are commonly preferred because of their lower toxicity and 
higher stability to pH and ions than ionic and amphiphilic surfactants [14]. The 
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hydrophilic-lipophilic balance (HLB) is a measure of the degree to which a substance 
is hydrophilic or lipophilic [15]. A HLB value of 20 defines a fully hydrophilic molecule, 
while a value of 0 defines a lipophilic one [16]. The stability of emulsions depends 
also on the ratio between the high HLB and low HLB surfactant amounts [12, 17]. As 
shown in Figure 3.6, among all the investigated surfactants, Ibuprofen exhibited 
quite higher solubility in Transcutol HP (HLB 4.2), 694 ± 30 mg ml
−1
; Labrasol (HLB 
14), 598 ± 12 mg ml
−1
; Cremophor RH40 (HLB 13), 339 ± 21 mg ml
−1
; and Capryol 
90 (HLB 6), 306 ± 10 mg ml
−1
 that have been selected for further investigations. 
Moreover, the optimal formulation is not only determined by the drug solubility but 
also by the emulsification efficiency and surfactant synergistic effect. 
 
Figure 3.6 Solubility of Ibuprofen in various vehicles; each value is expressed as 
mean ±σ (n = 3). 
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3.2. Construction of ternary phase diagrams 
The ternary phase diagrams of SNEDDS were constructed to screen the 
optimized SNEDDS. Before the construction of ternary phase diagrams, the 
miscibility between high HLB surfactants and oils was investigated to select the best 
components. While Labrasol (HLB 14) was poorly mixed with castor essential oil and 
soybean oil, other mixtures resulted in clear or milky homogenous solutions. 
Due to the fact that all surfactants are potentially irritant or are poorly tolerated 
[18], therefore large amounts of surfactants may cause gastrointestinal tract irritation 
[19]; systems which contain a higher proportion of essential oil should be preferred. 
The ternary phase diagrams of SNEDDS selected according to the previous criteria 
are shown in Figures 3.7 (A)–(C). The shadow areas enclosed in the triangle 
represented the self-emulsification regions. SNEDDS made of lemon essential oil, 
Labrasol and Transcutol HP (Figure 3.7 (B)) showed the largest self-emulsification 
region, with an improved self-emulsification capacity at decreasing the oil 
component amounts, thanks to the reduction in interfacial tension caused by higher 
content of the surfactant [20]. At a Cremophor RH40 (HLB 13) concentration higher 
than 60% (Figure 3.7 (A)) and a Labrafil M1944CS (HLB 4) concentration higher 
than 50% (figure 2(C)), self-emulsification didn’t occur, confirming that emulsification 
is determined not only by the surfactant or co-surfactant but also by the synergistic 
effect of the two. 
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Figure 3.7 Ternary phase diagrams for SNEDDS: (A) Lemon oil/Cremophor 
RH40/Transcutol HP; (B) Lemon oil/Labrasol/Transcutol HP; (C) Lemon 
oil/Labrasol/Labrafil M1944CS. The shadow areas represent the self-emulsification 
regions. 
3.3. Droplet size analysis 
As reported in [18, 21], smaller droplet sizes induce a higher intestinal absorption 
rate. The ternary contour of SEDDS as a function of lemon essential oil, Cremophor 
RH40 and Transcutol HP amounts (Figure 3.8) indicated that self-emulsification 
occurred with a droplet size smaller than 750 nm, both with phosphate buffer saline 
(PBS, pH 6.8) and simulated gastric acid (SGA, pH 2.0). 
With the increasing surfactant amount, the droplet size in emulsion decreased for 
both cases. Moreover, droplets were smaller in a SGA medium. 
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Figure 3.8 Ternary contour for droplet size of the lemon oil/Crempohor 
RH40/Transcutol HP system: (A) Emulsified with PBS (Phosphate buffered saline, 
pH 6.8); (B) Emulsified with SGA (Simulate gastric acid, pH 2.0). The colors 
represent different droplet sizes (from 0 to 750 nm). 
3.4. Optimization and characterization of Ibuprofen-loaded SNEDDS 
3.4.1. Solubility studies in optimized formulations 
Eight formulations (F1–F8, Table 3.1) with the smaller droplet size have been 
selected for the further optimization studies. Ibuprofen solubility increased in a 
higher amount surfactant and a co-surfactant containing formulations. However, a 
high level of surfactant and co-surfactant is reported to induce irritation and other 
negative gastrointestinal issues. 
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Table 3.1 Composition of optimized SNEDDS formulations and Ibuprofen solubility. 
 
 
 
 
 
 
3.4.2. Evaluation of viscosity, emulsification time and emulsion appearance 
for ibuprofen-loaded SNEDDS formulations 
The viscosity of the SNEDDS formulations is relevant for the manufacturing of 
formulation filled in soft or hard gelatin capsules [22, 23]. Too low viscosity of the 
formulations would hinder the capsule sealing effectively and enhance the 
probability of leakage, whereas too high viscosity may create the problems of 
pourability and emulsification capacity [22-25]. Ibuprofen content was chosen as 200 
mg/ml, because higher drug contents reduced the self-emulsification capacity. The 
results showed an increase of the formulation viscosity with increasing surfactant 
proportion in the formulations with values for the optimal formulations ranging from 
7.0 ± 0.1 to 42.0 ± 0.2 centipoise, depending on the formulation composition (Table 
3.2). The measured values are in agreement with the values required for the above 
described filling process. [26]. 
Apart from the viscosity, the emulsification time and emulsion appearance were 
also observed. The self-emulsification time of all formulations was less than 20 
seconds, and decreased with the decrease of viscosity. It means that SNEDDS 
Formulation 
number 
Lemon oil/Crempohor 
RH40 (Surf)/Transcutol HP 
(Co-surf) [v/v/v, %] 
Solubility 
(±σ) [mg/ml] 
F1 70/20/10 219±4 
F2 60/30/10 241±3 
F3 60/20/20 277±5 
F4 50/30/20 299±1 
F5 50/20/30 334±5 
F6 40/50/10 285±3 
F7 40/40/20 321±2 
F8 40/20/40 392±3 
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formulations could disperse quickly and completely under gentle agitation. Except 
emulsion F1 (7.0 ± 0.1 centipoise) that was cloudy after dilution, other emulsions 
appeared translucent, this being perhaps related to the larger droplet size of 
formulation 1.Viscosity was a crucial in affecting the emulsifying efficiency but 
played a negligible role on the droplet size. This results well agreed with some 
previous studies [2, 27-29]. 
 
Table 3.2 Viscosity, emulsification time and emulsion appearance of the optimized 
ibuprofen-loaded SNEDDS formulations, ibuprofen contents was 200mg/ml. 
 
Formulation 
number 
Viscosity 
(±σ) [mPa•s] 
Self-emulsification 
time (±σ) [s] 
Emulsion 
appearance 
F1 7.0 ± 0.1 8 ± 2 Cloudy 
F2 10.6 ± 0.1 10 ± 2 Translucence 
F3 8.0 ± 0.1 9 ± 2 Translucence 
F4 14.2 ± 0.2 10 ± 2 Translucence 
F5 9.5 ± 0.1 9 ± 2 Translucence 
F6 42.0 ± 0.2 18 ± 2 Translucence 
F7 33.1 ± 0.3 15 ± 2 Translucence 
F8 25.9 ± 0.2 13 ± 2 Translucence 
 
3.4.3. Droplet size and ζ-potential 
Droplet size, PDI and ζ-potential of the optimized SNEDDS in SGA with (200 mg 
ml
−1
) and without Ibuprofen are listed in Table 3.3. In agreement with [24], a slight 
increase in droplet size is observed for the Ibuprofen-loaded SNEDDS. This can be 
attributed to the preferential dissolution of the drug in the interfacial film (formed by 
the surfactant and co-surfactant) that increases the interfacial tension. Moreover, the 
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addition of the drug could induce surfactant aggregation, thus reducing its efficiency. 
The PDI values are below 0.40, which indicates that the droplets are uniform in size. 
The ζ-potential is correlated to the electrostatic repulsion and aggregation of the 
droplets. High positive or negative ζ-potential values (higher electrostatic repulsive 
forces) prevent coalescence, thus conferring stability of the emulsions [11, 22]. As 
shown in Table 3.3, all the SNEDDS emulsions had high negative ζ-potential values. 
The negative charges are due to the presence of free fatty acids in the surfactant 
and cosurfactant [14, 30]. The ζ-potential of the Ibuprofen-loaded SNEDDS was 
found to range between −35 ± 1 and −46 ± 1 mV, which indicated that the emulsions 
were stable. The ζ-potentials of Ibuprofen-loaded emulsion showed higher negative 
charges because of the negatively charged carboxyl groups in the Ibuprofen 
molecule. 
The droplet size of F4 with ibuprofen was found to be 31 ± 3 nm (Figure 3.9 A) 
with PDI of 0.20 ± 0.02. The zeta potential of the emulsion developed by F4 was 
found to be 38 ± 1 mV (Figure 3.9 B). The conductivity of the emulsion was 0.109 ± 
0.009 mS/cm, which means the emulsion was fine oil in water (conductivity > 10 
μS/cm) [19]. 
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Table 3.3 Droplet size, DPI and ζ-potential of 200μl optimized SNEDDS in 500 ml 
SGA (pH 2.0) at room temperature, with and without drug. 
 
 
 
 
Figure 3.9 Droplet size distribution (A) and zeta potential (B) of ibuprofen-loaded F4 
emulsion. 
Formulation 
number 
Without drug With drug (200mg/ml) 
Droplet size 
(±σ) [nm] 
DPI 
(±σ) 
ζ-potential 
(±σ) [mV] 
Droplet size 
(±σ) [nm] 
DPI 
(±σ) 
ζ-potential 
(±σ) [mV] 
F1 98 ± 1 0.21±0.01 -33±1 138±7 0.28±0.08 -38±1 
F2 71 ± 5 0.19±0.01 -31±1 98±8 0.19±0.02 -35±1 
F3 87 ± 6 0.32±0.04 -31±1 93±7 0.27±0.05 -37±1 
F4 13 ± 3 0.18±0.02 -33±1 31±3 0.20±0.02 -38±1 
F5 67 ± 8 0.31±0.04 -34±1 87±5 0.24±0.04 -40±1 
F6 41 ± 5 0.22±0.05 -42±1 53±8 0.31±0.02 -46±1 
F7 30 ± 4 0.34±0.08 -38±1 70±5 0.32±0.01 -42±2 
F8 47 ± 7 0.25 ±0.05 -39±1 57±7 0.29±0.01 -44±1 
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3.4.4. Formulation stability 
The stability of F4, i.e. the formulation producing the smallest droplets after three 
freezing/thawing cycles, is summarized in Table 3.4. The droplet size increased with 
no significant changes of the ζ-potential after three freezing/thawing cycles. 
Moreover, the formulation didn’t exhibit any drug precipitation or phase separation 
during the whole process. No marked difference of droplet size was observed for 
formulations stored at 4 ℃ or 25 ℃ (Table 3.5). The above findings indicated that 
this Ibuprofen-loaded formulation is thermodynamically stable. 
 
Table 3.4 Effects of freezing/thawing cycles on the dynamic characteristics of 
nanoemulsions obtained from F4 (Lemon oil/Crempohor RH40/ Transcutol HP with 
ratio 50/30/20, v/v/v) containing 200mg/ml Ibuprofen in SGA (pH 2.0, 500ml). 
 
Freezing/thawing 
cycle 
Droplet size 
(±σ) [nm] 
DPI 
(±σ) 
ζ-potential 
(±σ) [mV] 
- 31±3 0.20±0.02 -38±1 
First 36±8 0.22±0.02 -39±2 
Second 43±5 0.15±0.02 -38±2 
Third 44±4 0.19±0.03 -39±2 
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Table 3.5 Effects of storage conditions on the dynamic characteristics of 
nanoemulsion obtained from F4 (Lemon oil/Crempohor RH40/ Transcutol HP with 
ratio 50/30/20, v/v/v) containing 200mg/ml Ibuprofen in SGA (pH2.0, 500ml). 
 
Storing Time 
[months] 
Temp=4℃ Temp=25℃ 
Droplet size 
(±σ) [nm] 
DPI 
(±σ) 
Droplet size 
(±σ) [nm] 
DPI 
(±σ) 
1 36±3 0.21±0.02 36±5 0.23±0.03 
2 34±3 0.35±0.01 33±4 0.29±0.02 
3 33±5 0.25±0.03 34±3 0.35±0.02 
 
3.4.5. Morphological characterization 
The morphology of F4 Ibuprofen-loaded emulsion droplets was observed by TEM. 
As shown in Figure 3.10, droplets are spherical with a diameter range of 20–40 nm, 
according to the light scattering data (Table 3.3). 
 
 
Figure 3.10 TEM image of F4 Ibuprofen-SNEDDS (lemon oil/ Crempohor 
RH40/Transcutol HP with ratio 50/30/20, v/v/v) nanoemulsion. 
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3.4.6. Drug in vitro release study 
The Ibuprofen in vitro release in SGA for the eight selected optimal formulations 
emulsified in PBS and Ibuprofen suspended in PBS was evaluated for 4 h at 38 ℃ 
(Figure 3.11), following the previously described method. The drug release from 
SNEDDS was significantly greater than that of the Ibuprofen suspension. In 2 h, all 
the SNEDDS released approximately 80% of drug, with respect to 40% of the 
Ibuprofen suspension. All the SNEDDS released almost all drug in 4 h, with just a 
small difference among the different SNEDDS that are consistent with the droplet 
sizes (Table 3.3). In addition, the release from SNEDDS was faster, further 
supporting the hypothesis that nano-scale emulsions can improve the release of 
lipophilic drugs. 
On the other hand, the droplet size was related with the pH of dilution medium, 
which maybe affect the drug release efficiency. Figure 3.12 represents the release 
profile of three batches emulsions which were formulated with PBS and SGA, then 
released in the both media. B1 was diluted with PBS (pH=6.8), released in SGA 
(pH=2.0); B2 was diluted with SGA, released in SGA; B3 was diluted with SGA, 
released in PBS. Comparing B1 with B2, the pH change of dilution media did not 
bring marked difference, this possibly because the droplet size of both batches was 
small enough and had weak effect on the drug release. Comparing the release of B2 
and B3, the release in PBS is more effective than that in SGA.  A possible 
explanation was that ibuprofen exhibited acidity, which renders it less soluble at low 
pH. Similar results were reported earlier [31].  
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Figure 3.11 In vitro release profile of Ibuprofen suspension and Ibuprofen-SNEDDS 
(Emulsified with PBS, pH = 6.8, 10 ml) in SGA (pH = 2.0, 500 ml). 
 
Figure 3.12 In vitro release profile of F4 in both SGA and PBS. B1-Dilution with PBS, 
release in SGA; B2-Dilution with SGA, release in SGA; B3-Dilution with SGA, 
release in PBS. 
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4. Conclusion 
In the present chapter, a novel SNEDDS was successfully designed as a stable, 
high essential oil ratio (50%) and high drug-loaded (approximate 20%) formulation 
for the solubility and dissolution rate enhancement of Ibuprofen, chosen as a model 
for the lipophilic drug. The formulation composition and pH of the emulsifying 
medium significantly impacted the droplet size. The stability study confirmed that the 
SNEDDS formulations could withstand various storage conditions with excellent 
stability. The in vitro drug release study demonstrated that the release from 
SNEDDS was more efficient when compared with the drug suspension. Under these 
circumstances, the present SNEDDS would be a promising novel system to improve 
the lipophilic drug’s dissolution rate and potentially the bioavailability. 
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Chapter IV A novel pH-sensitive self-nanoemulsifying drug delivery system for 
acid-labile lipophilic drugs 
 
 
Oral administration is the most convenient way of all the drug delivery routes. 
Orally administered bioactive compounds must resist the harsh acidic fluids or 
enzyme digestion in stomach, to reach their absorbed destination in small intestine. 
This is the case for silibinin, a drug used to protect liver cells against toxins that has 
also been demonstrated in vitro to possess anti-cancer effects. However, as many 
other drugs, silibinin can degrade in the stomach due to the action of the gastric fluid. 
The use of pH-sensitive self-nanoemulsifying drug delivery systems (pH-SNEDDS) 
could overcome the drawback due to degradation of the drug in the stomach while 
enhancing its solubility and dissolution rate. 
In this paper we have investigated pH-sensitive self-nanoemulsifying formulations 
containing silibinin as model drug. Pseudo-ternary phase diagrams have been 
constructed in order to identify the self-emulsification regions under different pH. 
Solubility of silibinin in selected formulations has been assessed and stability of the 
pure drug and of the silibinin loaded pH-SNEDDS formulations in simulated gastric 
fluid had been compared. Droplet size of the optimized pH-SNEDDS has been 
correlated to pH, volume of dilution medium and silibinin loading amount. TEM 
(Transmission electron microscopy) studies have shown that emulsion droplets had 
spherical shape and narrow size distribution. In vitro drug release studies of the 
optimal pH-SNEDDS indicated substantial increase of the drug release and release 
rate in comparison to pure silibinin and to the commercial silibinin tablet. The results 
indicated that pH-SNEDDS have potential to improve the biopharmaceutics 
properties of acid-labile lipophilic drugs. 
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1. Introduction 
Oral drug delivery is the most favorable route for drug administration. However, 
nearly half of the currently drugs exhibit low solubility in water, which leads to limited 
oral bioavailability, developments and clinical applications [1, 2]. Various approaches 
such as the use of lipid nanoparticles [3], liposomes [4] and self-emulsifying 
formulations [5], have been developed to improve the bioavailability and dissolution 
rate of poor water-soluble drugs. Among them, self-nanoemulsifying drug delivery 
systems (SNEDDS), spontaneously forming nano-droplets emulsion in water have 
acquired growing interest. SNEDDS are isotropic mixtures of drug, surfactant and 
co-surfactant that can rapidly form fine oil-in-water emulsions upon mild agitation in 
an aqueous media with a droplet size in the range 50-200 nm [6, 7]. The dissolution 
of lipophilic drug in these nano-droplets combined with the small size and the larger 
surface area results in higher loading and improved bioavailability of the drug [8, 9].  
Generally drug absorption occurs at the small intestine where absorption is more 
effective due to the presence of villi and microvilli [10]. To reach the intestine (pH 
7.0-9.0) [11, 12], drugs must however resist the extremely low pH (pH 1.0-2.0) and 
enzymes in the stomach. Furthermore, some drugs could irritate the stomach, and, 
in addition, some lipophilic drugs have poor enteral absorption. 
Silibinin (also known as silybin), is a potent and principal component of silymarin 
extracted from the silybum marianum (Milk thistle) [13]. Silibinin has been used as a 
natural remedy for hepatitis, cirrhosis and recently has been reported to possess 
anticancer activity [14]. Unfortunately, silibinin is poorly bioavailable, due to its 
degradation in the gastric fluid, low water solubility and poor enteral absorption [15-
17]. 
In order to prevent degradation of acid-labile lipophilic drugs in the stomach, 
several approaches have been attempted. Among those, pH sensitive drug carriers 
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have been proposed also to exploit the physiological pH gradient between gastric 
juice and the intestinal tract [18, 19]. 
So far, there are no publications on self-nanoemulsifying systems displaying pH 
sensitive properties. The aim of the present study was to develop a pH-sensitive 
self-nanoemulsifying drug delivery system (pH-SNEDDS) to increase solubility and 
dissolution of silibinin, thereby enhancing its oral bioavailability potentially. This 
formulation could moreover protect the drug from the acidic degradation in the 
stomach while facilitating the release in small intestine thanks to self-
nanoemulsification (Figure 4.1). Drug solubility and loading in the formulations, 
nano-emulsions droplet size and stability, and in vitro drug release have been 
evaluated. 
 
Figure 4.1 Schematic outline of the human digestive tract with pH-sensitive self-
nanoemulsifying drug delivery system. 
2. Materials and methods 
2.1. Materials 
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Silibinin and Oleic acid were purchased from Sigma Aldrich S.r.l (Milan, Italy). 
Mono/diglycerides of caprylic acid (Capmul MCM C8 EP) was received as gift 
sample from ABITEC Corporation (Janesville, United states). Tablets (Cardo 
mariano) containing 11 mg silibinin in 500 mg excipients were purchased from ALCH 
Co. (Giarre, Italy). All other chemicals used were analytical reagent grade. 
Deionized water was used through the whole study. 
2.2. Construction of pseudo-ternary phase diagrams 
Mixtures of low and high HLB (hydrophilic-lipophilic balance) surfactants are 
necessary for developing stable emulsions [8, 20]. Different ratios of oleic acid (as 
precursor of the hydrophilic surfactant) and Capmul MCM C8 (as hydrophobic 
surfactant), in the range 1:9 to 9:1, were used to identify the self-emulsification 
regions at 37.0±0.5 ℃ through the construction of pseudo-ternary phase diagrams. 
Oleic acid is a fatty acid, which included in the normal human diet as a part of 
animal fats and vegetable oils. Meanwhile, Capmul MCM C8 EP is a proven 
pharmaceutical excipient which meets the requirements of the European 
Pharmacopoeia Monograph for “Glycerol Monocaprylate” Type I [21]. The usage of 
Capmul MCM C8 EP for oral bioavailability enhancement was firstly reported by 
Panayiotis et al [22] for enhancing intestinal absorption of an RGD peptide in 1995, 
as well as the site-specific drug delivery[23]. 
Additionally, the modified visual examination method reported by Villar et al [7] 
was used to determine the self-emulsification regions. Briefly, the above 
formulations were magnetically stirred for 1 day, and 250 μl of each formulation was 
added drop by drop into 50 ml sodium phosphate buffer solution (PBS, pH range 
was between 6.8 and 8.0) under gentle magnetic stirring at 37.0±0.5 ℃ (Figure 4.2). 
The generated mixtures with clear or milk-white color were considered as self-
emulsifying emulsion. All the assays were repeated three times. The pseudo-ternary 
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phase diagrams were constructed using Origin software (OriginLab Corporation, 
USA). 
 
Figure 4.2 Set-up for preparation of nanoemulsions by the pH-sensitive self-
emulsification method. 
2.3. pH stability of silibinin 
Silibinin stock solution (300 mg silibinin in 10 ml ethanol) was added into various 
buffer solutions (pH 1.0, 3.0, 6.8, 7.0, 7.2, 7.4 and 8.0, in order to simulate all 
physiological pHs), at a concentration of about 100 ppm silibinin. Solutions were 
mixed under gentle magnetic stirring at 37.0±0.5 ℃ for 4 hours and aliquots of 200 
μl were periodically sampled and the amount of silibinin was determined by UV 
spectrophotometry (Nanodrop, Thermo Scientific, Wilmington, USA) at 288 nm 
wavelength. A calibration curve was constructed to correlate the height of the UV 
peaks to the weight concentration of silibinin in solution, using the method reported 
by Sooväli L et al [24]. Degradation was taken as the ratio between the silibinin 
content after the stability assay and the initial silibinin loading. Three consecutive 
measurements were made for each sample, and the results were presented as the 
mean and standard deviation. 
2.4. Optimization and characterization of silibinin loaded pH-SNEDDS 
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2.4.1. Drug solubility in formulations 
The solubility of silibinin in various formulations was measured by Nanodrop 
spectrophotometry. An excess of silibinin (approximately 200 mg) was placed in 1 ml 
different ratios oleic acid/Capmul MCM C8 formulations in sealed vials and the 
mixture was vortex-mixed at 37.0±0.5 ℃ for 48 hours in a water-bath to facilitate 
the dissolution. Finally, drug saturated formulations were centrifuged at 10000 x g 
for 30 min with a SIGMA 2-16 Centrifuge (SIGMA Laborzentrifugen GmbH, 
Osterode am Harz, Germany). The supernatant was filtered through a 0.2 μm PTFE 
filter membrane to remove the undissolved silibinin, and filtrates were diluted and 
analyzed by Nanodrop. The pure formulations without drug were used as reference. 
This assay was repeated in triplicate for each formulation. 
2.4.2. Silibinin stability in the SNEDDS formulation in simulated gastric fluid 
  Silibinin stability was studied in simulated gastric fluid (SGF, 0. 1 M HCl solution 
with 0.9% NaCl) at pH 1.0. In brief, 10mg silibinin was introduced to 5ml of each 
formulation and vortex-mixed for 24 hours at room temperature. After attaining 
equilibrium, the formulations were added into SGF at 37.0±0.5 ℃ under gentle 
magnetic stirring for 4 hours, and aliquots of 20 μl were taken out periodically and 
filtered through 0.2 μm PTFE filter membrane for the analysis by Nanodrop. Each 
sample was studied in triplicate. 
2.4.3. Fourier transform infrared (FTIR) spectroscopy 
  Fourier transform infrared (FTIR) spectroscopy was carried out to detect the 
possible chemical property change of silibinin in excipients and formulations. The 
FT-IR spectra in the range of 650 - 4000 cm
-1
 for pure silibinin, physical mixtures of 
silibinin with Capmul MCM C8 EP and oleic acid, and silibinin loaded pH-SNEDDS 
formulations were observed at a resolution of 2 cm
-1
 using Spectrum One 
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spectrometer with ATR correction (Perking Elmer, Waltham, MA, USA) with Zinc 
Selenide crystal. 
2.4.4. Differential scanning calorimetry (DSC) 
The thermal characteristics of silibinin powder, physical mixture of drug with 
excipients, and optimal SNEDDS formulation were investigated using a differential 
scanning calorimetry (Mettler DSC 30, Mettler-Toledo, OH, USA). The samples were 
placed in aluminum pans, while an empty pan was used as reference. The DSC 
scans were recorded at a heating rate of 10 ℃/min from 25 ℃ to 250 ℃ under a 
nitrogen flow (100ml/min). 
2.4.5. Determination of droplet size 
Droplet size of emulsions was measured by dynamic light scattering (Zetasizer 
Nano-ZS, Malvern Instruments, Worcestershire, UK) at a scattering angle of 90°. 
The liquid pH-SNEDDS emulsions were filled in a disposable cuvette after diluting 
five times with deionized water, and shaken gently to mix thoroughly. All 
measurements taken at room temperature were repeated three times, and the 
values of average diameters and standard deviation (σ) were determined. 
2.4.6. Formulation stability study 
The stability of optimal drug-loaded formulations was evaluated by exposing the 
formulations to three freeze-thaw cycles, which consisted of freezing at 4 ℃ for 24 h 
followed by thawing at 65 ℃ for 24 h in an incubator. The droplet size, PDI and ζ-
potential of the emulsions were investigated after each cycle. Moreover, accelerated 
stability of formulations were evaluated for droplet size and PDI at 4 ℃ and 25 ℃ for 
up to 6 months, respectively. 
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2.4.7. Droplets morphology characterization 
Transmission electron microscope (TEM, Philips CM12 microscope, Netherland) 
was employed to study the morphology of silibinin loaded pH-SNEDDS emulsions. 
One drop of emulsion was placed on a carbon coated copper grid and the water 
removed by drying in the hood. Subsequently, samples were stained with 2% (v/v) 
phosphotungstic acid solution and dried again before the analysis. The operating 
voltage of TEM was 120 kV. 
2.4.8. In vitro drug release 
The in vitro drug release of silibinin loaded pH-SNEDDS at 37.0±0.5 ℃  was 
evaluated as follows. 30 ml of drug loaded pH-SNEDDS emulsions (containing 10 
mg silibinin), 10 mg silibinin in PBS at pH 7.4 as the control and milled commercial 
silibinin tablet suspension (equivalent to 10 mg silibinin in PBS of pH 7.4) were 
introduced into sealed dialysis membrane tubings (MWCO: 12-14000 Da, 
Spectrum○R ). Tubings were suspended in glass beakers containing 500 mL 
simulated intestinal fluid (sodium phosphate buffer solution, pH 7.4) as release 
medium, magnetically stirred at 100 rpm. An aliquot (200 μl) of the medium was 
periodically collected, replaced with an equal amount of fresh medium, and analyzed 
for the content of silibinin by Nanodrop spectrophotometry. All measurements were 
performed in triplicate. 
2.5. Statistics 
All the results were represented as mean and standard deviation (σ). Statistical 
analysis was performed with GraphPad Prism software (GraphPad Software Inc., 
California, U.S.A) using one way analysis of variance (ANOVA). 
3. Results and discussion 
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3.1. Construction of pseudo-ternary phase diagrams 
Pseudo-ternary phase diagrams of pH-SNEDDS have been constructed to identify 
the self-emulsifying regions for the optimized formulations. Before the construction 
of the pseudo-ternary phase diagram, a series of formulations have been screened 
to assess their pH responsiveness.  
The pseudo-ternary phase diagrams of the selected pH-SNEDDS at various pH 
are shown in Figure 4.3. The whole gray area represent the self-emulsification 
region in the pH range 6.8-8.0 while the light gray area focusing on the self-
emulsification region at pH 6.8 -7.0. For pH>7.0, the emulsification region is wider 
due to the fact that above that pH more free carboxylic groups of oleic acid are 
ionized [25, 26]. Consequently, the synergistic effects between hydrophilic and 
lipophilic surfactant are more effective [27]. 
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Figure 4.3 Pseudo-ternary phase diagram for pH-SNEDDS: The whole gray area 
represents the self-emulsification region between pH 6.8 and 8.0, while the area in 
light gray is the self-emulsification region at pH 6.8 -7.0. 
 
3.2. Optimization and solubility study of pH-SNEDDS 
Three pH-SNEDDS formulations have been selected from the pseudo-ternary 
phase diagram for further optimization. Their composition and silibinin solubility data 
are reported in Table 4.1. The higher silibinin solubility of F1 is consistent with the 
higher amount of the hydrophobic component Capmul MCM C8 EP. 
Appearance of F2 pH-SNEDDS in various buffer solutions from pH 1.0 to 8.0 is 
illustrated in Figure 4.4. pH-SNEDDS formulations are stable in acidic medium (pH 
1.0 and 3.0), being able to resist harsh gastric fluids and protect the drug. 
Emulsification is only partial at pH 6.8, while improves at higher pH consistently with 
the pH range (7.0 to 9.0) of the small intestine [11, 12]. 
 
Table 4.1 Composition of optimized pH-SNEDDS formulations and silibinin solubility. 
Data expressed as μ ± σ (n = 3). 
 
Formulation 
number 
Oleic acid/ Capmul MCM C8 EP 
[v/v,%] 
Silibinin solubility (±σ) 
[mg/ml] 
F1 30/70 89.1±8.7 
F2 40/60 71.9±9.5 
F3 50/50 29.9±7.7 
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Figure 4.4 Photographs of pH-SNEDDS (F2) at various pH (up) and enlargements of 
the interface layers (down) at pH6.8 (left) and 7.2 (right). DiI, a lipophilic dye, was 
added to distinguish the formulations. 
 
3.3. pH stability of silibinin 
Besides the poor water solubility, utilization of silibinin is also limited by its 
degradation in gastric fluid [15, 28]. Figure 4.5 A indicates that silibinin concentration 
in the solution decreased by 80% in the first 5 minutes at pH 1.0 and 3.0, with 
degradation of only about 10% in 4 hours under basic pH between 7.2 and 8.0. The 
above finding is in agreement with the results reported by Patel A. et al [16]. 
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Figure 4.5 Degradation of pure silibinin at various physiological pH (A) and silibinin 
in selected formulations in simulated gastric fluid (pH=1.0, B). The results are 
presented as μ ± σ (n=3). 
3.4. Silibinin stability in formulation 
Studies of silibinin stability in formulations during gastric incubation (pH=1.0) at 
37±0.5 ℃ for 4 hours (Figure 4.5 B) , showed that silibinin degrades less than 20% 
from the optimized formulations in comparison with the pure silibinin (more than 
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90%), thus indicating that pH-sensitive self-emulsifying formulations protect silibinin 
from simulated acidic fluids. 
3.5. Fourier transformed infrared spectroscopy (FTIR) 
FTIR spectra of pure silibinin, physical mixture of silibinin with Capmul MCM C8 
EP and oleic acid, silibinin loaded optimal pH-SNEDDS formulations are 
demonstrated in Figure 4. The characteristic peaks at 3452 cm−1 can be attributed 
to the presence of hydroxyl group (–OH), while the peak at 1631 cm−1 is associated 
with the C=O stretching of the carboxylic acid group (–COOH). Similar FTIR 
observation are reported by the works of Tan et al. [29] and Pooja D et al [30]. The 
spectra of both physical mixtures and silibinin loaded optimal formulations (F1 and 
F2) don’t show any changes in characteristic peak position from silibinin spectrum, 
indicating the absence of chemical nature change of silibinin in the formulations. 
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Figure 4.6 FTIR spectra of pure silibinin, physical mixtures of silibinin with Capmul 
MCM C8 EP and oleic acid, and silibinin loaded optimal pH-SNEDDS formulations 
(F1 and F2). 
3.6. Differential scanning calorimetry (DSC) 
Differential scanning calorimetry was used to investigate the thermal behavior of 
the pure silibinin and the excipients with silibinin (Figure 4.7). Silibinin showed an 
endothermic peak at 166.31 ℃ with onset at 147.79 ℃ and endset at 174.76 ℃ that 
corresponds to the melting point of silibinin in crystalline form. No endothermic 
peaks were found in the physical mixtures of optimal formulations, Capmul MCM C8 
EP, and oleic acid, indicating that silibinin must be molecularly dissolved in an 
amorphous state in the formulations.  
 
Figure 4.7 Differential scanning calorimetry thermogram of pure silibinin, physical 
mixtures of silibinin with Capmul MCM C8 EP and oleic acid, silibinin loaded optimal 
pH-SNEDDS formulations (F1 and F2). 
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3.7. Determination of droplet size 
The droplet size distribution of emulsions is one of the most important factors for 
the self-emulsification performance. The smaller the droplet size, the higher the drug 
dissolution and intestinal absorption rate is. Due to the low solubility of silibinin in F3, 
only F1 and F2 have been compared in the following assays. 
3.7.1. Droplet size at different pH 
The effect of the emulsifying medium pH on the droplet size of silibinin pH-
SNEDDS emulsions is reported in Figure 4.8. A slight increase in droplet size is 
observed for the silibinin loaded emulsions in comparison to that without drug for 
both F1 and F2. This can be attributed to the drug dissolution in the oil-water 
interfacial films, which increases the interfacial tension, and leads the droplet size 
enlargement. In addition, the presence of drug could induce surfactant aggregation, 
thus reducing the efficiency of surfactants [31]. An increase of pH from 7.0 to 8.0 
resulted in the decrease of droplet size. F2 has smaller droplets than F1 under the 
same pH conditions. 
 
Figure 4.8 Effect of emulsifying medium pH on the droplet size of silibinin loaded pH-
SNEDDS emulsions. Formulations were diluted a 200 fold. Each value is 
represented as μ ± σ (n=3). 
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3.7.2. Droplet size by dilution medium volume 
The effect of dilution medium volume on droplet size is showed in Figure 4.9 A for 
formulations with and without drug. The dilution does not appreciably affect the 
droplet size, which proves the formulation stability under the variable dilution 
conditions that could result after the oral administration.  
 
Figure 4.9 Effect of dilution medium volume (A) and silibinin loaded amount (B) on 
droplet size of pH-SNEDDS emulsions. Dilution medium was sodium phosphate 
buffer solution with pH 7.4. Each value is represented as μ ± σ (n=3). 
3.7.3. Droplet size by different drug loading 
The droplet size profiles of pH-SNEDDS emulsion from each formulation have 
been estimated by gradually increasing drug loading (Figure 4.9B). In this 
investigation, a noticeable increase of the droplets diameter has been observed at 
increasing drug loading for both formulations, however still mantaining the size in the 
nano-range. For F2, maximum test drug loading is 60 mg/ml, because of the 
relatively limited dissolution of silibinin in this formulation (71.9 ± 9.5 mg/ml). 
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3.8. Formulation stability 
The results of characterization of F1 with silibinin after three freeze/thaw cycles 
were summarized in Table 4.2. The droplet size slightly increased with no significant 
changes of the ζ-potential. The accelerated stability of F1 was also investigated 
under different storage conditions (Table 4.3). The results suggested that no 
significant changes occurred on droplet size and PDI of the formulated emulsions. 
Thus, it could be concluded that this formulation was thermodynamically stable at 
harsh storage conditions as well as accelerated conditions. 
Table 4.2 Parameters of nanoemulsions obtained from F1 (Oleic acid/ Capmul MCM 
C8 EP with ratio 30/70, v/v) containing 60 mg/ml silibinin during freeze thaw cycles. 
Dilution medium was sodium phosphate buffer solution with pH 7.4. Data reported 
are μ ± σ (n = 3). 
Freeze thaw cycle Droplet size (±σ) 
[nm] 
PDI 
(±σ) 
ζ-potential 
(±σ) [mV] 
Initial 189 ± 11 0.15 ± 0.03 38 ± 3 
First 190 ± 9 0.19 ± 0.04 36 ± 4 
Second 192 ± 13 0.21 ± 0.02 37 ± 3 
Third 193 ± 11 0.22 ± 0.04 38 ± 2 
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Table 4.3 Accelerated stability data of nanoemulsions obtained from F1 (Oleic acid/ 
Capmul MCM C8 EP with ratio 30/70, v/v) containing 60 mg/ml silibinin. Dilution 
medium was sodium phosphate buffer solution with pH 7.4. Data reported are mean 
± σ (n = 3). 
Time 
(months) 
Temp=4 ℃ Temp=25 ℃ 
Droplet size 
(±σ) [nm] 
PDI (±σ) Droplet size 
(±σ) [nm] 
PDI (±σ) 
1 189 ± 9 0.22 ± 0.02 187 ± 14 0.29 ± 0.04 
3 192 ± 11 0.25 ± 0.03 195 ± 9 0.28 ± 0.01 
6 197 ± 12 0.28 ± 0.01 191 ± 12 0.30 ± 0.03 
 
3.9. Morphology characterization 
The TEM morphology of F1 silibinin loaded pH-SNEDDS emulsion droplets is 
shown in Figure 4.10. Nano-droplets are spherical in shape, uniform in size from 150 
nm to 200 nm, in accordance with dynamic light scattering data (Figure 4.9). 
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Figure 4.10 TEM image of F1 silibinin pH-SNEDDS (60mg/ml) nanoemulsions. 
Formulation was diluted a 200 fold in the emulsifying medium (PBS, pH 7.4). 
3.10. In vitro drug release study 
The in vitro drug release was carried out for silibinin loaded pH-SNEDDS, silibinin 
suspension and milled commercial silibinin tablet suspension (Product from 
ALCH○R ). As shown in Figure 4.11, silibinin released from suspension was less than 
10% in 9 hours, with much lower drug release from the tablets. In contrast, within 9 
hours approximately 70% and 80% of silibinin are released from pH-SNEDDS F1 
and F2, respectively. The significant release enhancement by pH-SNEDDS can be 
attributed to its amorphous nature, smaller droplet size and increased surface area 
[30]. In addition, F2 has shown higher release than F1, because of the relatively 
smaller droplet size of F2 emulsions, that is consistent with the droplet sizes study 
(Figure 4.9). 
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Figure 4.11 Comparison of in vitro release of optimized silibinin loaded pH-SNEDDS 
(Emulsified with PBS, pH=7.4), silibinin suspension and milled commercial silibinin 
tablet suspension (Product from ALCH○R ). Data expressed as μ ± σ (n = 3). 
 
 
 
4. Conclusions 
The present chapter describes an innovative approach for protecting acid-labile 
bioactive compounds and improving the solubility and dissolution rate of lipophilic 
drugs by using pH-sensitive self-emulsifying formulations. In particular, pH-SNEDDS 
protected silibinin from the harsh acidic gastric-like fluids while providing excellent 
self-emulsification in intestinal tract. Further, the formulation stability study 
demonstrated that the formulations were stable under various storage conditions. 
Increasing the emulsifying medium pH leads droplet size decrease, while size 
significantly increasing together with drug loading. In vitro release profile from pH-
SNEDDS was much higher than from powder and commercial tablets product, thus 
resulting more effective as drug carrier. 
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Accordingly, we concluded that the pH-SNEDDS could enhance the bioavailability 
of lipophilic drugs, and represent a new route for the oral administration of acid-labile 
drug delivery systems. 
 
Acknowledgments 
 
The present work is partially funded by One More Step Erasmus Mundus (2012-
2015) project from EU. The authors wish to acknowledge Dr Mauro Dalla Serra from 
CNR and Dr Gloria Ischia from the University of Trento, for their great assistance on 
the sample characterization. The authors also acknowledge ABITEC Corp. for 
supplying surfactant and samples. 
 
 
References 
[1] Buyukozturk F, Benneyan JC, Carrier RL. Impact of emulsion-based drug delivery systems on intestinal 
permeability and drug release kinetics. Journal Of Controlled Release 2010;142:22-30. 
[2] Kohli K, Chopra S, Dhar D, Arora S, Khar RK. Self-emulsifying drug delivery systems: an approach to enhance 
oral bioavailability. Drug Discovery Today 2010;15:958-65. 
[3] Naeem M, Kim W, Cao J, Jung Y, Yoo JW. Enzyme/pH dual sensitive polymeric nanoparticles for targeted drug 
delivery to the inflamed colon. Colloids And Surfaces B-Biointerfaces 2014;123:271-8. 
[4] Wang T, Wang N, Wang TY, Sun WR, Li TF. Preparation of submicron liposomes exhibiting efficient 
entrapment of drugs by freeze-drying water-in-oil emulsions. Chemistry And Physics Of Lipids 2011;164:151-7. 
[5] Ghai D, Sinha VR. Nanoemulsions as self-emulsified drug delivery carriers for enhanced permeability of the 
poorly water-soluble selective beta(1)-adrenoreceptor blocker Talinolol. Nanomedicine-Nanotechnology Biology 
And Medicine 2012;8:618-26. 
[6] Mazzaferro S, Bouchemal K, Ponchel G. Oral delivery of anticancer drugs III: formulation using drug delivery 
systems. Drug Discovery Today 2013;18:99-104. 
[7] Villar AMS, Naveros BC, Campmany ACC, Trenchs MA, Rocabert CB, Bellowa LH. Design and optimization of 
self-nanoemulsifying drug delivery systems (SNEDDS) for enhanced dissolution of gemfibrozil. International 
Journal of Pharmaceutics 2012;431:161-75. 
[8] Agrawal AG, Kumar A, Gide PS. Self emulsifying drug delivery system for enhanced solubility and dissolution 
of glipizide. Colloids And Surfaces B-Biointerfaces 2015;126:553-60. 
[9] Gao F, Zhang ZW, Bu HH, Huang Y, Gao ZW, Shen JN, Zhao CJ, Li YP. Nanoemulsion improves the oral 
absorption of candesartan cilexetil in rats: Performance and mechanism. Journal Of Controlled Release 
2011;149:168-74. 
[10] Pang KS. Modeling of intestinal drug absorption: Roles of transporters and metabolic enzymes (for the Gillette 
Review Series). Drug Metabolism And Disposition 2003;31:1507-19. 
[11] Aron-Wisnewsky J, Dore J, Clement K. The importance of the gut microbiota after bariatric surgery. Nature 
Reviews Gastroenterology & Hepatology 2012;9:590-8. 
[12] Belzer C, de Vos WM. Microbes inside-from diversity to function: the case of Akkermansia. Isme Journal 
2012;6:1449-58. 
103 
 
[13] Wang YC, Zhang L, Wang QW, Zhang DR. Recent Advances in the Nanotechnology-Based Drug Delivery of 
Silybin. Journal Of Biomedical Nanotechnology 2014;10:543-58. 
[14] Biedermann D, Vavrikova E, Cvak L, Kren V. Chemistry of silybin. Natural Product Reports 2014;31:1138-57. 
[15] El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal 
delivery system: Preparation and experimental design investigation. International Journal of Pharmaceutics 
2006;308:140-8. 
[16] Patel A, Heussen P, Hazekamp J, Velikov KP. Stabilisation and controlled release of silibinin from pH 
responsive shellac colloidal particles. Soft Matter 2011;7:8549-55. 
[17] Tang N, Wu D, Lu Y, Chen J, Zhang B, Wu W. A comparative study on the stability of silybin and that in 
silymarin in buffers and biological fluids. Drug metabolism letters 2009;3:115-9. 
[18] Hu Y, Wang JS, Zhang H, Jiang GQ, Kan CY. Synthesis and characterization of monodispersed P(St-co-
DMAEMA) nanoparticles as pH-sensitive drug delivery system. Materials Science & Engineering C-Materials for 
Biological Applications 2014;45:1-7. 
[19] Liu J, Huang YR, Kumar A, Tan A, Jin SB, Mozhi A, Liang XJ. pH-Sensitive nano-systems for drug delivery in 
cancer therapy. Biotechnology Advances 2014;32:693-710. 
[20] Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-
microemulsifying' drug delivery systems. European Journal of Pharmaceutical Sciences 2000;11:S93-S8. 
[21] Corp. A. Technical Data Sheet of Capmul MCM C8, EP.  2015. 
[22] Constantinides PP, Lancaster CM, Marcello J, Chiossone DC, Orner D, Hidalgo I, Smith PL, Sarkahian AB, 
Yiv SH, Owen AJ. Enhanced intestinal absorption of an RGD peptide from water-in-oil microemulsions of different 
composition and particle size. Journal Of Controlled Release 1995;34:109-16. 
[23] Yeh P-Y, Berenson MM, Samowitz WS, Kopečková P, Kopecek J. Site-specific drug delivery and penetration 
enhancement in the gastrointestinal tract. Journal Of Controlled Release 1995;36:109-24. 
[24] Sooväli L, Rõõm E-I, Kütt A, Kaljurand I, Leito I. Uncertainty sources in UV-Vis spectrophotometric 
measurement. Accreditation and quality assurance 2006;11:246-55. 
[25] El-Sherbiny IM, Abdel-Mogib M, Dawidar AAM, Elsayed A, Smyth HDC. Biodegradable pH-responsive 
alginate-poly (lactic-co-glycolic acid) nano/micro hydrogel matrices for oral delivery of silymarin. Carbohydrate 
Polymers 2011;83:1345-54. 
[26] Thanki K, Gangwal RP, Sangamwar AT, Jain S. Oral delivery of anticancer drugs: Challenges and 
opportunities. Journal Of Controlled Release 2013;170:15-40. 
[27] Palmer D, Levina M, Douroumis D, Maniruzzaman M, Morgan DJ, Farrell TP, Rajabi-Siahboomi AR, 
Nokhodchi A. Mechanism of synergistic interactions and its influence on drug release from extended release 
matrices manufactured using binary mixtures of polyethylene oxide and sodium carboxymethylcellulose. Colloids 
And Surfaces B-Biointerfaces 2013;104:174-80. 
[28] Blumenthal M, Goldberg A, Brinckmann J. Herbal Medicine-Inte grative Medicine Communications. Austin 
2000;8:401. 
[29] Tan JM, Karthivashan G, Arulselvan P, Fakurazi S, Hussein MZ. In vitro nanodelivery of silibinin as an 
anticancer drug under pH response. Journal Of Drug Delivery Science And Technology 2014;24:579-84. 
[30] Pooja D, Bikkina DJB, Kulhari H, Nikhila N, Chinde S, Raghavendra YM, Sreedhar B, Tiwari AK. Fabrication, 
characterization and bioevaluation of silibinin loaded chitosan nanoparticles. International Journal Of Biological 
Macromolecules 2014;69:267-73. 
[31] Zhao TJ, Maniglio D, Chen J, Chen B, Motta A, Migliaresi C. Design and optimization of self-nanoemulsifying 
formulations for lipophilic drugs. Nanotechnology 2015;26. 
 
104 
 
 
Chapter V Summary and Future perspectives 
 
1. Summary 
The overall objective of the present thesis was to design and optimize self-
nanoemulsifying drug delivery systems (SNEDDS) for poor water soluble drugs oral 
delivery.     
  Chapter III focused on the development and optimization of a surfactant reduced 
amount SNEDDS with high proportion of essential oil as carrier for lipophilic drugs. 
In fact, surfactants are generally toxic, moreover the large amount of surfactants 
used in SNEDDS could provoke irritation to GI tract.  
A second study, described in chapter VI, aimed at exploiting self-nanoemulsifying 
drug delivery systems for controlled release. In spite of the many efforts that have 
been done on the design and production of the novel self-emulsifying formulations 
as alternatives to conventional SEDDS, there is no approved controlled release self-
emulsifying product available.  
Some drugs are prone to degradation, undesired inactivation or irritation in the GI 
tract. The developed pH-sensitive self-nanoemulsifying formulations in our work 
have been shown to be able to protect acid-labile drug, control drug release, 
increase drug solubility and potentially enhance the oral bioavailability. Combination 
of SNEDDS and pH sensitive technique represents a new route for the oral 
administration of acid-labile drug delivery systems. 
2. Future perspectives 
Since nearly 40% of recent new drug substances are lipophilic, it appears that 
more drug products will be formulated as SEDDS for the pharmaceutical market in 
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the very near future. The challenges associated with the formulation of self-
emulsifying systems include the selection of right excipients with consideration of 
their solvent capacity, miscibility, chemical stability, dispersibility, regulatory issues, 
and so on. Although the potential utility of SEDDS has been known for decades, it is 
only in recent years that a mechanistic understanding of their impact on drug 
disposition has emerged [1]. To this end, more predictive in vitro models are needed 
for predicting the changes involving the drug in SEDDS in the gut, so that the fate of 
the drug in vivo can be more reliably monitored [2]. The applications of SNEDDS in 
other routes of delivery apart from the oral route can be explored. Besides, other 
techniques may be combined with self-emulsification to develop multifunctional drug 
delivery systems. With future developments in this novel technology, SEDDS will 
remove deficiencies associated with delivery of poorly soluble drugs. Thus, this field 
requires further exploration and research to bring out a wide range of commercially 
available self-emulsifying formulations [1]. 
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